Hospira 10-Q 6 Nov 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2014	Nov. 03, 2014
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'HOSPIRA INC	'
Entity Central Index Key	'0001274057	'
Document Type	'10-Q	'
Document Period End Date	30-Sep-14	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--12-31	'
Entity Current Reporting Status	'Yes	'
Entity Filer Category	'Large Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	169,202,014
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Income (Loss) and Comprehensive Income (Unaudited) (USD $)	3 Months Ended		9 Months Ended
In Millions, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Statement of Comprehensive Income [Abstract]	'	'	'	'
Net sales	$1,150.60	$1,008.20	$3,337.20	$2,918.40
Cost of products sold	719.3	718	2,136.30	2,159.50
Restructuring, impairment and (gain) on disposal of assets, net	-106.3	9.8	-92	21.4
Research and development	86.3	69.9	245.2	218.1
Selling, general and administrative	223.8	180.7	621.1	556
Total operating costs and expenses	923.1	978.4	2,910.60	2,955
Income (Loss) From Operations	227.5	29.8	426.6	-36.6
Interest expense	19.2	23.3	58.9	62.8
Other expense, net	4.3	39	1.4	51.3
Income (Loss) Before Income Taxes	204	-32.5	366.3	-150.7
Income tax expense (benefit)	48.6	-31.7	84.1	-96.2
Equity income from affiliates, net	-3.2	-2.7	-15.2	-12.7
Net Income (Loss)	158.6	1.9	297.4	-41.8
Earnings (Loss) Per Common Share:	'	'	'	'
Basic (in dollars per share)	$0.94	$0.01	$1.77	($0.25)
Diluted (in dollars per share)	$0.92	$0.01	$1.75	($0.25)
Weighted Average Common Shares Outstanding:	'	'	'	'
Basic (in shares)	168.9	165.7	167.7	165.5
Diluted (in shares)	171.8	167	170.2	165.5
Comprehensive Income (Loss):	'	'	'	'
Foreign currency translation adjustments, net of taxes of $0.0 million for all periods	-96.3	-5.5	-57.6	-139.3
Pension liability adjustments, net of taxes of $(1.1) million and $(1.9) million for the three months ended September 30, 2014 and 2013, respectively, and $(3.7) million and $(5.6) million for the nine months ended September 30, 2014 and 2013, respectively	2.1	2.9	5.9	9
Unrealized losses on marketable equity securities, net of taxes of $0.0 million for all periods	-2.7	0	-2.1	0
(Losses) gains on cash flow hedges, net of taxes of $0.0 million and $1.3 million for the three months ended September 30, 2014 and 2013, respectively, and $0.0 million and $1.4 million for the nine months ended September 30, 2014 and 2013, respectively	0	-2.3	0.1	-2.4
Other Comprehensive Loss	-96.9	-4.9	-53.7	-132.7
Net Income (Loss)	158.6	1.9	297.4	-41.8
Comprehensive Income (Loss)	$61.70	($3)	$243.70	($174.50)

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Income and Comprehensive Income (Parenthetical) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Statement of Comprehensive Income [Abstract]	'	'	'	'
Foreign currency translation adjustments, taxes	$0	$0	$0	$0
Pension liability adjustments, taxes	-1.1	-1.9	-3.7	-5.6
Unrealized (losses) gains on marketable equity securities, taxes	0	0	0	0
Reclassification of gains on terminated cash flow hedges, taxes	$0	$1.30	$0	$1.40

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Cash Flow From Operating Activities:	'	'
Net Income (Loss)	$297.40	($41.80)
Adjustments to reconcile Net Income (Loss) to net cash from operating activities-	'	'
Depreciation	134.7	128.9
Amortization of intangible assets	60.8	63.8
Loss on early debt extinguishment	0	33.4
Stock-based compensation expense	40.3	31.1
Undistributed equity income from affiliates	-15.2	-12.7
Distributions received from equity affiliates	16.3	30.1
Deferred income taxes and other tax adjustments	12.8	-119.7
Impairments and other asset charges	7.3	73.1
Gain on disposal of assets	-100.8	-0.9
Changes in assets and liabilities, net of the effects of acquisitions-	'	'
Trade receivables	-57.4	11.2
Inventories	-100.4	-144.3
Prepaid expenses and other assets	-8.2	-48.7
Trade accounts payable	33.4	-11.3
Other liabilities	-0.3	60
Other, net	13.6	9.3
Net Cash Provided by Operating Activities	334.3	61.5
Cash Flow From Investing Activities:	'	'
Capital expenditures (including instruments placed with or leased to customers)	-279	-248.5
Acquisitions, net of cash acquired	-223.4	0
Purchases of intangibles and other investments	-35.2	-12.2
Purchase of debt security	-200	0
Proceeds from disposal of businesses and assets	130.7	1.4
Net Cash Used in Investing Activities	-606.9	-259.3
Cash Flow From Financing Activities:	'	'
Issuance of long-term debt, net of fees paid	0	691.8
Repayment of long-term debt	0	-650
Payment on early debt extinguishment	0	-39.8
Other borrowings, net	-84.8	56
Excess tax benefit from stock-based compensation arrangements	4.4	1.1
Proceeds from stock options exercised	105.9	13
Net Cash Provided by Financing Activities	25.5	72.1
Effect of exchange rate changes on cash and cash equivalents	-9.6	-14.6
Net change in cash and cash equivalents	-256.7	-140.3
Cash and cash equivalents at beginning of period	798.1	772.1
Cash and cash equivalents at end of period	541.4	631.8
Cash paid during the period-	'	'
Interest	101.7	93.7
Income taxes, net of refunds	40.6	55.7
Accrued capital expenditures	$27.90	$12.20

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Unaudited) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Current Assets:	'	'
Cash and cash equivalents	$541.40	$798.10
Trade receivables, less allowances of $10.3 and $11.2, respectively	610.2	574.3
Inventories, net	1,190	1,066.20
Deferred income taxes and other	215.2	208.6
Prepaid expenses	71.3	90
Other receivables	131.1	101.3
Total Current Assets	2,759.20	2,838.50
Property and equipment, net	1,787.70	1,574.20
Intangible assets, net	145.1	172.2
Goodwill	1,093	1,057.70
Deferred income taxes	314.6	358.9
Investments	257.1	33.1
Other assets	136.4	144.3
Total Assets	6,493.10	6,178.90
Current Liabilities:	'	'
Short-term borrowings	12.9	93.7
Trade accounts payable	356.1	329.2
Salaries, wages and commissions	212.7	185.4
Other accrued liabilities	588.2	556.8
Total Current Liabilities	1,169.90	1,165.10
Long-term debt	1,749.20	1,747
Deferred income taxes	6.9	3.2
Post-retirement obligations and other long-term liabilities	215.4	301.7
Commitments and Contingencies	'	'
Total Shareholders' Equity	3,351.70	2,961.90
Total Liabilities and Shareholders' Equity	$6,493.10	$6,178.90

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Statement of Financial Position [Abstract]	'	'
Trade receivables, allowances	$10.30	$11.20

Condensed_Consolidated_Stateme3

Condensed Consolidated Statement of Changes in Shareholders' Equity (USD $)	Total	Common Stock	Treasury Stock	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Loss
In Millions, unless otherwise specified
Balances at Dec. 31, 2013	$2,961.90	$1.80	($599.80)	$1,838.10	$1,923.80	($202)
Common stock outstanding (shares)	169.1	'	'	'	'	'
Increase (Decrease) in Shareholders' Equity	'	'	'	'	'	'
Net Income	297.4	'	'	'	'	'
Other comprehensive loss	-53.7	0	0	0	0	-53.7
Changes in shareholders' equity related to incentive stock programs	146.1	0	0	146.1	0	0
Changes in shareholders' equity related to insentive stock programs (in shares)	'	3.1	'	'	'	'
Balances at Sep. 30, 2014	$3,351.70	$1.80	($599.80)	$1,984.20	$2,221.20	($255.70)
Balances (in shares) at Sep. 30, 2014	'	169.1	'	'	'	'

Basis_of_Presentation_and_Sign

Basis of Presentation and Significant Accounting Policies	9 Months Ended
	Sep. 30, 2014
Basis of Presentation and Significant Accounting Policies [Abstract]	'
Basis of Presentation and Significant Accounting Policies	'
	Basis of Presentation and Significant Accounting Policies
	Description of Business
	Hospira, Inc. ("Hospira") is a provider of injectable drugs and infusion technologies that it develops, manufactures, distributes and markets globally. Hospira's portfolio includes generic injectables, biosimilars, and integrated infusion therapy and medication management products. Hospira's broad portfolio of products is used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities.
	Hospira conducts operations worldwide and is managed in three reportable segments: Americas; Europe, Middle East and Africa ("EMEA"); and Asia Pacific ("APAC"). See Note 25 for further information.
	Basis of Presentation
	The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission for interim reporting and, therefore, do not include all information and footnote disclosures normally included in audited financial statements in conformity with generally accepted accounting principles in the U.S. ("GAAP"). However, in the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary to present fairly the results of operations, financial position and cash flows have been made. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in Hospira's Annual Report on Form 10-K for the year ended December 31, 2013 ("2013 Form 10-K"). The results of operations for any interim period are not necessarily indicative of the results of operations to be expected for the full year.
	Adoption of New Accounting Standards
	In February 2013, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2013-04, "Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation Is Fixed at the Reporting Date" ("ASU 2013-04"). ASU 2013-04 provides guidance for the recognition, measurement and disclosure of obligations resulting from joint and several liability arrangements for which the total amount of the obligation within the scope of ASU 2013-04 is fixed at the reporting date. The guidance requires an entity to measure those obligations as the sum of the amount the reporting entity agreed to pay on the basis of its arrangement among its co-obligors, as well as any additional amount the reporting entity expects to pay on behalf of its co-obligors. ASU 2013-04 also requires an entity to disclose the nature and amount of those obligations. ASU 2013-04 was first effective for reporting periods beginning after December 15, 2013, with early adoption permitted. Retrospective application was required. Hospira adopted ASU 2013-04 in the first quarter of 2014. There was no material impact to Hospira's condensed consolidated financial position, results of operations or cash flows upon adoption of this guidance.
	In March 2013, the FASB issued ASU 2013-05, "Parent's Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity" ("ASU 2013-05"). ASU 2013-05 clarifies the applicable guidance for the release of cumulative translation adjustments into net income when a reporting entity either sells a part or all of its investment in a foreign entity or ceases to have a controlling financial interest in a subsidiary or group of assets that constitute a business within a foreign entity. ASU 2013-05 was first effective prospectively for reporting periods beginning after December 15, 2013, with early adoption permitted. Hospira adopted ASU 2013-05 in the first quarter of 2014. There was no material impact to Hospira's condensed consolidated financial position, results of operations or cash flows upon adoption of this guidance.
	In July 2013, the FASB issued ASU 2013-11, "Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists" ("ASU 2013-11"). ASU 2013-11 requires, unless certain conditions exist, an unrecognized tax benefit, or a portion of an unrecognized tax benefit, to be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, similar tax loss, or a tax credit carryforward. ASU 2013-11 was first effective prospectively for reporting periods beginning after December 15, 2013, with early adoption permitted. Retrospective application was permitted. Hospira prospectively adopted ASU 2013-11 in the first quarter of 2014, and as a result, reduced long-term Deferred income taxes assets and Post-retirement obligations and other long-term liabilities presented on the condensed consolidated balance sheet by approximately $25.0 million. There was no material impact to Hospira's condensed consolidated financial position, results of operations or cash flows upon adoption of this guidance.
	In April 2014, the FASB issued ASU 2014-08, "Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity" ("ASU 2014-08"). ASU 2014-08 amends guidance for reporting discontinued operations and disposals of components of an entity. ASU 2014-08 requires that a disposal representing a strategic shift that has (or will have) a major effect on an entity's financial results or a business activity classified as held for sale be reported as discontinued operations. The guidance also expands the disclosure requirements for discontinued operations and adds new disclosures for individually significant dispositions that do not qualify as discontinued operations. ASU 2014-08 is effective prospectively for fiscal years, and interim reporting periods within those years, beginning after December 15, 2014 with early adoption permitted only for disposals that have not been previously reported. Hospira adopted ASU 2014-08 in the third quarter of 2014. There was no material impact to Hospira's condensed consolidated financial position, results of operations or cash flows upon adoption of this guidance.
	Recently Issued Accounting Standards
	In May 2014, the FASB issued ASU 2014-09, "Revenue from Contracts with Customers" ("ASU 2014-09"). ASU 2014-09 supersedes nearly all existing revenue recognition guidance under GAAP. The core principle of ASU 2014-09 is to recognize revenues to depict the transfer of promised goods or services to customers in an amount that reflects the consideration that is expected to be received for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle. ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2016. Early adoption is not permitted. Hospira is currently evaluating the impact of ASU 2014-09 on its condensed consolidated financial statements and related disclosures.
	In June 2014, the FASB issued ASU 2014-12, "Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period" ("ASU 2014-12"). ASU 2014-12 requires that a performance target which affects vesting and could be achieved after the requisite service period be treated as a performance condition in accordance with ASC 718, Compensation - Stock Compensation. ASU 2014-12 is effective prospectively for annual periods beginning after December 15, 2015 with early adoption permitted. Hospira is currently evaluating the impact of ASU 2014-12 on its condensed consolidated financial statements and related disclosures.
	Significant Accounting Policies
	Supplier Advances
	Hospira has outstanding advances, net of inventory receipts, of $50.5 million to Celltrion, Inc. and Celltrion Healthcare, Co., Ltd. (collectively "Celltrion") through September 30, 2014 for the purchase of certain biosimilar products. Additional supplier advances in the aggregate of $25.0 million for these biosimilar products may be required over the next two years, the timing of which is based on estimated regulatory approval dates and commercial launch dates. Hospira may distribute and market additional products sourced from Celltrion which would require additional advances.
	Total supplier advances were $54.9 million and $102.2 million as of September 30, 2014 and December 31, 2013, respectively. A portion of the decrease in supplier advances relates to the acquisition of Orchid Chemicals & Pharmaceuticals Ltd.'s ("Orchid") penem and penicillin Active Pharmaceutical Ingredient ("API") business, as further described in Note 2. The current and long-term portions are reported in Prepaid expenses and Other assets, respectively, in the condensed consolidated balance sheets. Supplier advances are in some cases long-term, refundable under certain conditions, either interest bearing or interest free, primarily unsecured and subject to credit risk.
	Unapproved Products
	Hospira capitalizes product costs, material and conversion costs in preparation for product launches prior to regulatory approval when regulatory approval of the products is considered probable. Unapproved product inventories were $42.8 million and $7.1 million as of September 30, 2014 and December 31, 2013, respectively, and the current and long-term portions are reported in Prepaid expenses and Other assets, respectively, in the condensed consolidated balance sheets. Unapproved product reserves were $7.0 million and $2.3 million as of September 30, 2014 and December 31, 2013, respectively.

Business_Acquisition

Business Acquisition	9 Months Ended
	Sep. 30, 2014
Business Combinations [Abstract]	'
Business Acquisition	'
	Business Acquisitions
	Orchid (Penem and Penicillin Active Pharmaceutical Ingredient Business & Associated Research and Development Facility)
	On July 4, 2014, Hospira, through its wholly-owned subsidiary, Hospira Healthcare India Private Limited ("Hospira India"), acquired from Orchid its penem and penicillin API business located in Aurangabad, India, and associated research and development ("R&D") facility based in Chennai, India, along with the related assets and employees associated with these operations, for a preliminary purchase price of $247.2 million, subject to certain adjustments. This acquisition provides Hospira additional API capacity and allows for continued vertical integration of anti-infective penem and penicillin products. The purchase price, based on the final purchase agreement terms, includes foreign currency exchange rate impacts, working capital adjustments, the assumption of debt, and settlement of $29.5 million of amounts due to Hospira from Orchid. In addition, a portion of the purchase price, $17.0 million, is subject to an eighteen month hold-back. Pursuant to the terms of the purchase agreement, some or all of such hold-back amount may ultimately be retained by Hospira.
	Also on July 4, 2014, Hospira advanced, through a loan facility, approximately $17.3 million to an entity controlled by the primary shareholder of Orchid to fund obligations of this entity necessary to close the transaction. Hospira will pursue collection in accordance with the terms of the facility, however, as collectability is not reasonably assured, an allowance was established and reported in Selling, general and administrative in the three and nine months ended September 30, 2014.
	The following summarizes acquisition and integration-related costs:
	(dollars in millions)		Three Months Ended September 30,				Nine Months Ended September 30,
			2014		2013		2014		2013
	Cost of products sold		$	1.9	$	—	$	1.9	$	—
	Selling, general and administrative		24.8		1.2		27.6		3.9
	Total		$	26.7	$	1.2	$	29.5	$	3.9
	Cumulative acquisition and integration-related costs as of September 30, 2014 were $35.1 million.
	The assets acquired and liabilities assumed at their respective estimated fair values is preliminary and based on the initial measurements as of the acquisition date of July 4, 2014. The fair value of intangible assets and acquired in-process research and development ("IPR&D") is pending finalization of the valuation, which may result in significant adjustments, and will be completed as soon as practicable. The following table summarizes the fair value of the assets acquired and liabilities assumed, based on management's best estimate:
	(dollars in millions)
	Current assets, net	$	53.5
	Property and equipment	120.1
	Intangible assets (product rights)	18
	IPR&D	13
	Goodwill	48.7
	Other non-current assets and liabilities, net	(6.1		)
	Total allocation of purchase price	$	247.2
	Intangible assets (product rights) have an estimated weighted average useful life of 9 years. IPR&D is considered an indefinite-lived intangible asset until completion, regulatory approval or discontinuation, at which point Hospira will make a determination as to the useful life of the intangible asset and begin amortization. Goodwill, primarily assigned to the Americas reportable segment, includes the expected synergies and other benefits that Hospira believes will result from the integrated operations. Goodwill is not expected to be deductible for tax purposes.
	Separately, Orchid remains a current supplier of cephalosporin APIs to Hospira.
	Evolabis
	In February 2014, Hospira acquired a Brazilian-based oncology distributor, Evolabis Produtos Farmacêuticos Ltda., adding approximately 15 on-market oncology products to Hospira's portfolio in Brazil, accelerating expansion of its injectable pharmaceutical product line.
	The operating results of the acquisitions have been included in Hospira's results of operations since the individual acquisition dates, and pro forma results of operations for these acquisitions have not been presented as they are not material to Hospira's results of operations, either individually or in the aggregate.

Restructuring_Actions

Restructuring Actions	9 Months Ended
	Sep. 30, 2014
Restructuring and Related Activities [Abstract]	'
Restructuring Actions	'
	Restructuring and Optimization Actions
	Hospira aims to achieve a culture of continuous improvement to enhance its efficiency, effectiveness and competitiveness and improve its cost base. As part of this strategy, Hospira has taken a number of actions to reduce operating costs and optimize operations. The net charges related to these actions consist primarily of severance and other employee benefits, other exit costs, contract termination costs and gains or losses on disposal of assets.
	Restructuring
	From time to time Hospira incurs costs to implement restructuring actions for specific initiatives. In late 2012 and continuing into 2014, Hospira incurred costs to optimize commercial organizational structures, in all segments, and exit device products in certain APAC markets. As Hospira continues to optimize its global commercial operations and align investments to support future growth, Hospira anticipates that similar restructuring actions will continue through 2015. The aggregate costs are reported in Restructuring, impairment and (gain) on disposal of assets, net and primarily include severance charges of $13.6 million and contract termination charges of $2.3 million. Of the aggregate costs, $(0.6) million and $3.1 million were (released) incurred in the three months ended September 30, 2014 and 2013, respectively, and $1.4 million and $7.6 million were incurred in the nine months ended September 30, 2014 and 2013, respectively.
	The following summarizes the aggregate restructuring activity for the nine months ended September 30, 2014:
	(dollars in millions)	Employee-Related			Other			Total
		Benefit Costs
	Balance at January 1, 2014	$	2.5		$	1.8		$	4.3
	Costs (releases)	2.2			(0.8		)	1.4
	Payments	(2.9		)	(0.4		)	(3.3		)
	Balance at September 30, 2014	$	1.8		$	0.6		$	2.4
	Facilities Optimization
	In April 2014, Hospira agreed to sell its Buffalo, NY, manufacturing facility. As part of this agreement, the buyer purchased substantially all manufacturing facility assets and entered into an agreement to manufacture the components and sub-assemblies Hospira produced in Buffalo for various Hospira manufacturing facilities. Hospira closed the transaction in July 2014 and incurred a pre-tax loss on disposal of assets of $5.0 million reported in Restructuring, impairment and (gain) on disposal of assets, net in the nine months ended September 30, 2014.
	Divestitures
	In August 2014, Hospira sold its surgical suction product line for $21.5 million payable in three installments through December 2015. Hospira will retain distribution rights to the products for varying periods of time depending on the territory and provide certain transition services through no later than December 2016. Hospira recognized a pre-tax gain of $15.9 million upon disposition of the product line reported in Restructuring, impairment and (gain) on disposal of assets, net in the three and nine months ended September 30, 2014.
	In September 2014, Hospira sold its clinical surveillance software business, TheraDoc, Inc. ("TheraDoc") for a purchase price of $117.0 million, subject to adjustments for ending working capital, cash and indebtedness. Hospira recognized a pre-tax gain of $89.9 million upon disposition of the business reported in Restructuring, impairment and (gain) on disposal of assets, net in the three and nine months ended September 30, 2014.

Device_Strategy

Device Strategy	9 Months Ended
	Sep. 30, 2014
Device Strategy [Abstract]	'
Device Strategy	'
	Device Strategy
	Hospira continues to implement its Device Strategy announced in May 2013, an initiative intended to establish a streamlined and modernized product portfolio addressing customer needs and positioning Hospira for future innovation and growth, while supporting continued advancement of device remediation, including device quality improvement efforts. The Device Strategy is anticipated to be completed during the second half of 2015. Actions include investments in (i) modernizing and streamlining Hospira's installed base of devices through retirement and replacement programs, (ii) strengthening device quality systems/processes and (iii) developing next generation technology, such as the Plum 360™ and SapphirePlus™ pumps, to support further modernization of its installed base. Under the retirement and replacement actions, Hospira is retiring older pumps from the market and initiating customer replacement programs. Among alternatives provided to customers, Hospira is offering customer sales allowances and/or accommodations which may be used as a credit for transitioning to alternative technology.
	In connection with the Device Strategy, Hospira expects to incur aggregate charges related to these actions in the range of approximately $300 million to $350 million on a pretax basis. The total estimated aggregate charges include pre-tax cash costs of approximately $240 million to $290 million. Major cash costs include the following: (i) customer sales allowances; (ii) customer accommodations, contract termination, and pump collection and destruction costs; and (iii) pump retirement and replacement program administration, quality systems/process improvement, consulting costs and other costs. Further, of the total pre-tax charges, approximately $60 million relates to non-cash charges for various asset charges, primarily pump inventory charges, other pump-related asset impairments and accelerated depreciation on production equipment and Hospira-owned pumps in service.
	Charges incurred for the Device Strategy, primarily in the Americas segment, were reported as follows:
		Three Months Ended September 30,				Nine Months Ended September 30,				Line Item in the
										Condensed Consolidated
	(dollars in millions)	2014		2013		2014		2013		Statement of Income (Loss)
	Customer sales allowances	$	—	$	—	$	—	$	104.3	Net sales
	Consulting, customer accommodations, contract termination, collection and destruction and other costs	2.7		14.8		12.3		56.1		Cost of products sold
	Inventory charges	0.6		0.9		3		46.7		Cost of products sold
	Other asset impairments and accelerated depreciation	—		3.2		1.3		10.3		Restructuring, impairment and (gain) on disposal of assets, net
	Total charges	$	3.3	$	18.9	$	16.6	$	217.4
	Cumulative Device Strategy charges as of September 30, 2014 were $243.5 million. The amount, timing and recognition of additional charges associated with the Device Strategy over the anticipated time period will be affected by the nature of spending and the occurrence of commitments and triggering events, among other factors.
	See Note 16 for Device Strategy related and other accrual activity for the nine months ended September 30, 2014.

Collaborative_Arrangements

Collaborative Arrangements	9 Months Ended
	Sep. 30, 2014
Collaborative Arrangements [Abstract]	'
Collaborative Arrangements	'
	Collaborative and Other Arrangements
	On April 29, 2013, Hospira and NovaQuest Co-Investment Fund I, L.P. ("NovaQuest") entered into an arrangement for three biosimilar products: Hospira's erythropoietin biosimilar ("EPO") (in the U.S. and Canada), filgrastim (in the U.S.) and pegylated filgrastim (globally). Hospira is responsible for research and development, regulatory approval, commercialization and distribution of these products. NovaQuest will contribute development funding up to $120.0 million with contributions not exceeding $50.0 million in any single year and such amounts are recorded as an offset to Research and development expense as incurred as there is substantive and genuine risk of return of the investment inherent in these biosimilar development programs. In exchange for the development funding, if applicable, Hospira will make milestone payments to NovaQuest upon achieving the first commercial sale for each product, and such payments will be expensed to Cost of products sold as incurred. Hospira will also be required to pay NovaQuest royalties based upon commercial net sales of the products. In certain instances that result in the delay or failure of the products to be marketed (other than the failure of the products to achieve regulatory approval), Hospira may be obligated to make certain payments to NovaQuest as compensation for such unanticipated events. In these circumstances, reimbursement will be made in the form of royalties related to certain sales of Hospira's on-market products. Hospira's total payments to NovaQuest inclusive of the milestones and royalties are capped at a multiple of development funding, which in any reported period could be significant. For the three and nine months ended September 30, 2014, in connection with the NovaQuest agreement, Hospira recognized an offset to Research and development expense for development funding of $9.4 million and $28.1 million, respectively. For the three and nine months ended September 30, 2013, the offset recognized to Research and development expense was $22.1 million and $36.4 million, respectively. Cumulative development funding from NovaQuest as of September 30, 2014 was $78.1 million.
	For information on other Hospira collaborative and other arrangements see Note 5 to Hospira's consolidated financial statements included in Hospira's 2013 Form 10-K.

Investments

Investments	9 Months Ended
	Sep. 30, 2014
Investments [Abstract]	'
Investments	'
	Investments
	Equity Method Investments
	Investments include equity-method investments in which Hospira has significant influence but not control over the investee. The majority of Hospira's equity-method investments consist of a 50% ownership interest in a joint venture, Zydus Hospira Oncology Private Limited ("ZHOPL") with Cadila Healthcare Limited, a pharmaceutical company located in Ahmedabad, India. Equity income from affiliates, net, including the ZHOPL equity investment, was $3.2 million and $2.7 million for the three months ended September 30, 2014 and 2013, respectively. Equity income from affiliates, net, including the ZHOPL equity investment, was $15.2 million and $12.7 million for the nine months ended September 30, 2014 and 2013, respectively. Distributions received from ZHOPL were $16.3 million and $30.1 million, for the nine months ended September 30, 2014 and 2013, respectively.
	Combined income statement financial information of unconsolidated equity method investments is as follows:
		Nine Months Ended September 30,
	(dollars in millions)	2014		2013
	Revenue	$	47.3	$	69.9
	Operating expenses	27.3		33.3
	Operating income	20		36.6
	Net Income	24.2		28.9
	Fair Value Investments
	On September 30, 2014, Hospira closed a convertible bond subscription agreement with Celltrion Healthcare Co., Ltd. ("Celltrion Healthcare"). Celltrion Healthcare issued a convertible bond with an aggregate principal amount denominated in Korean Won equal to $200.0 million U.S. Dollars, due on September 30, 2019. Interest will be payable quarterly at an annual rate of 6.0%. The convertible bond will be recognized as an available-for-sale investment and is subject to credit risk. Hospira may redeem some or all of the principal of the convertible bond for cash or an equity interest in Celltrion Healthcare, or, starting on the third anniversary of the issue of the convertible bond, the supply of biosimilar products. Additionally, Celltrion Healthcare may elect to pay interest on the convertible bond in cash, or in kind by providing biosimilar product to Hospira. Further, Hospira amended its co-exclusive agreement with Celltrion to amend commercial terms, which includes providing Hospira exclusive rights to specific biosimilar products in the U.S. and certain other territories. The terms of the convertible bond do not impact cumulative supplier advances already made from Hospira to Celltrion, described in "Note 1. Basis of Presentation and Significant Accounting Policies."
	Cost Method Investments
	In July 2014, Hospira advanced $30.0 million for an investment with a research and development venture with the potential obligation to invest an additional $15.0 million as early as 2015. In the initial phase of the agreement, the investment is fully refundable, subject to credit risk, to the extent certain development milestones are not met. The products developed are expected to provide Hospira commercialization opportunities in future periods.
	Impairments
	During the three and nine months ended September 30, 2013, Hospira recognized non-cash impairment charges of $2.7 million and $11.0 million, respectively, reported in Other expense, net to impair equity method investments. The impairments were primarily due to a decline in market value of the investments based on management's assessment of future cash flows or earnings from the investments.
	During the three and nine months ended September 30, 2013, Hospira assessed the decline in the market value of its marketable equity securities to be other-than-temporary, primarily due to the nature and severity of the investment's decline in market value and the near-term prospects for recovery to the original invested value. Accordingly, Hospira recognized impairment charges of $0.4 million and $3.5 million, respectively, reported in Other expense, net.

Fair_Value_Measures

Fair Value Measures	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Measures	'
	Fair Value Measures
	The following table summarizes the methodology used to measure certain assets and liabilities at fair value on a recurring basis in the condensed consolidated balance sheets:
				Fair Value Measurements at Reporting Date, Using:
				Quoted Prices		Significant
				in Active Markets for		Other
				Identical Items		Observable
		September 30,				Inputs		Significant
								Unobservable
								Inputs
	(dollars in millions)	2014		(Level 1)		(Level 2)		(Level 3)
	Financial Assets:
	Foreign currency exchange contracts	$	7.6	$	7.6	$	—	$	—
	Investments	201.6		4.1		197.5		—
	Financial Liabilities:
	Foreign currency exchange contracts	1.4		—		1.4		—
	See Note 6 for additional information on the Level 2 investment.
				Fair Value Measurements at Reporting Date, Using:
				Quoted Prices		Significant
				in Active Markets for		Other
				Identical Items		Observable
		December 31,				Inputs		Significant
								Unobservable
								Inputs
	(dollars in millions)	2013		(Level 1)		(Level 2)		(Level 3)
	Financial Assets:
	Foreign currency exchange contracts	$	2.8	$	—	$	2.8	$	—
	Investments	3.8		3.8		—		—
	Financial Liabilities:
	Foreign currency exchange contracts	0.1		—		0.1		—
	The fair value of Level 1 assets is based on quoted market prices of the identical underlying security in an active market. The fair value of Cash and cash equivalents, which include money market fund instruments, approximate their carrying value due to their short-term nature, and are within Level 1 of the fair value hierarchy. The fair value of Level 2 assets and liabilities is primarily based on market observable inputs to quoted market prices, benchmark yields and broker/dealer quotes. Level 3 inputs, as applicable, are unobservable inputs which reflect assumptions developed by management to measure assets and liabilities at fair value.
	The carrying values of certain financial instruments, primarily Trade receivables, Trade accounts payable and Short-term borrowings, approximate their estimated fair values due to their short-term nature. The carrying value and estimated aggregate fair value, based primarily on market prices (Level 1), of the senior unsecured notes are as follows:
		September 30, 2014				December 31, 2013
	(dollars in millions)	Carrying		Fair Value		Carrying		Fair Value
		Value				Value
	Senior unsecured notes	$	1,750.00	$	1,887.70	$	1,750.00	$	1,794.80

Financial_Instruments_and_Deri

Financial Instruments and Derivatives	9 Months Ended
	Sep. 30, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Financial Instruments and Derivatives	'
	Financial Instruments and Derivatives
	Hospira's operations are exposed to market risk primarily due to changes in currency exchange and interest rates. The objective in managing these risks is to reduce volatility on earnings and cash flows. To reduce the risk, Hospira enters into certain derivative financial instruments, when available on a cost-effective basis, to hedge its underlying economic exposure. For a more detailed description of Hospira's financial instruments and derivatives, see Note 8 to Hospira's consolidated financial statements included in Hospira's 2013 Form 10-K.
	In June 2014, Hospira closed foreign currency option contracts with an aggregate notional value of 10.0 billion Indian rupees, for a gain of $5.8 million. These contracts were entered into to mitigate a portion of the exposure resulting from movements of the U.S. dollar against the Indian rupee in connection with the purchase price for the acquisition of Orchid's penem and penicillin API business and related R&D facility. See Note 2 for further information regarding the acquisition. Since the derivatives were hedges of foreign currency risk for a business combination denominated in a foreign currency, the change in the value of the derivatives was recognized in Other expense, net in the condensed consolidated financial statements.
	The following table summarizes Hospira's fair value of outstanding derivatives:
		Condensed Consolidated Balance	September 30,			December 31,
	(dollars in millions)	Sheet Presentation	2014			2013
	Derivatives not designated as hedging instruments
	Foreign currency exchange contracts:	Other receivables	$	7.6		$	2.8
		Other accrued liabilities	1.4			0.1
	The impact on earnings from derivatives activity was as follows:
		Presentation of (Gain) Loss	Three Months Ended September 30,						Nine Months Ended September 30,
	(dollars in millions)	Recognized on Derivatives	2014			2013			2014			2013
	Derivatives not designated as hedging instruments
	Foreign currency exchange contracts	Other expense, net	$	(5.6	)	$	(3.0	)	$	(4.8	)	$	—

Inventories

Inventories	9 Months Ended
	Sep. 30, 2014
Inventory Disclosure [Abstract]	'
Inventories, net	'
	Inventories, Net
	Inventories, net consists of the following:
		September 30,		December 31,
	(dollars in millions)	2014		2013
	Finished products	$	513.4	$	442.3
	Work in process	358.5		294.1
	Materials	318.1		329.8
	Total	$	1,190.00	$	1,066.20
	Inventory reserves were $143.2 million and $143.3 million as of September 30, 2014 and December 31, 2013, respectively.

Property_and_equipment_net

Property and equipment, net	9 Months Ended
	Sep. 30, 2014
Property, Plant and Equipment [Abstract]	'
Property and equipment, net	'
	Property and Equipment, Net
	Property and equipment, net consists of the following:
		September 30,			December 31,
	(dollars in millions)	2014			2013
	Property and equipment, at cost	$	3,563.40		$	3,286.20
	Accumulated depreciation	(1,775.7		)	(1,712.0		)
	Total property and equipment, net	$	1,787.70		$	1,574.20

Goodwill_and_Intangible_assets

Goodwill and Intangible assets, net	9 Months Ended
	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill and Intangible assets, net	'
	Goodwill and Intangible Assets, Net
	The following summarizes Goodwill and Intangible assets, net activity:
					Intangible
	(dollars in millions)	Goodwill			assets, net
	Balance at January 1, 2014	$	1,057.70		$	172.2
	Additions	55.8			39.9
	Amortization	—			(60.8		)
	Disposals	(17.6		)	(4.9		)
	Currency translation effect	(2.9		)	(1.3		)
	Balance at September 30, 2014	$	1,093.00		$	145.1
	Additions to Goodwill and Intangible assets, net are primarily related to Hospira's acquisition of Orchid's penem and penicillin API business and Evolabis as discussed in Note 2, and are primarily assigned to the Americas reportable segment. Disposals of Goodwill are related to Hospira's disposals of TheraDoc and the surgical suction product line, as discussed in Note 3, and are a reduction primarily from the Americas reportable segment. See Note 25 for information on reportable segments.
	Intangible assets with definite lives are amortized on a straight-line basis over their estimated useful lives (1 to 16 years, weighted average 10 years). Indefinite lived intangibles, principally IPR&D, are not amortized until completion and regulatory approval. During the three months ended September 30, 2014 and 2013, intangible asset amortization expense was $16.6 million and $20.5 million, respectively, and reported in Cost of products sold. During the nine months ended September 30, 2014 and 2013, intangible asset amortization expense was $60.8 million and $63.8 million, respectively. Intangible asset amortization is estimated at $75 million for 2014, $47 million for 2015, $26 million for 2016, $16 million for 2017 and $7 million for 2018.
	Intangible assets, net consists of the following:
		Gross Carrying Amount						Accumulated Amortization						Intangible assets, net
		September 30,			December 31,			September 30,			December 31,			September 30,		December 31,
	(dollars in millions)	2014			2013			2014			2013			2014		2013
	Product rights and other	$	568.8		$	562.6		$	(461.2	)	$	(422.9	)	$	107.6	$	139.7
	Customer relationships	7.7			11.9			(6.4		)	(7.8		)	1.3		4.1
	IPR&D	13.8			2.2			—			—			13.8		2.2
	Technology	39			48.9			(16.6		)	(22.7		)	22.4		26.2
	Total	$	629.3		$	625.6		$	(484.2	)	$	(453.4	)	$	145.1	$	172.2

Other_Assets

Other Assets	9 Months Ended
	Sep. 30, 2014
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]	'
Other assets	'
	Other Assets
	Other assets consists of the following:
		September 30,		December 31,
	(dollars in millions)	2014		2013
	Supplier advances	$	29.1	$	59.8
	Net investment in sales-type leases, less current portion	13		19.9
	Unapproved products	32.6		—
	Non-current receivables	32.5		33
	All other	29.2		31.6
	Total	$	136.4	$	144.3

SalesType_Leases

Sales-Type Leases	9 Months Ended
	Sep. 30, 2014
Leases [Abstract]	'
Sales-Type Leases	'
	Sales-Type Leases
	The net investment in sales-type leases of certain medication management products consists of the following:
			September 30,			December 31,
	(dollars in millions)		2014			2013
	Minimum lease payments receivables		$	23.2		$	32.1
	Unearned interest income		(2.0		)	(3.3		)
	Net investment in sales-type leases		21.2			28.8
	Current portion (1)		(8.2		)	(8.9		)
	Net investment in sales-type leases, less current portion (1)		$	13		$	19.9
	(1)	The current and long-term portions are reported in Trade receivables and Other assets, respectively.
	Hospira monitors the credit quality of sales-type leases and recognizes an allowance for credit loss based on historical loss experience. As of September 30, 2014 and December 31, 2013, allowance for credit losses and amounts past due 90 days for sales-type leases were not material.

Other_Accrued_Liabilities

Other Accrued Liabilities	9 Months Ended
	Sep. 30, 2014
Payables and Accruals [Abstract]	'
Other Accrued Liabilities	'
	Other Accrued Liabilities
	Other accrued liabilities consists of the following:
		September 30,		December 31,
	(dollars in millions)	2014		2013
	Accrued rebates	$	134.7	$	150.4
	Income taxes payable	35.2		10.4
	Product recalls, customer sales allowances, customer accommodations and other related accruals	141.3		110.5
	Accrued returns	28.4		20.1
	All other	248.6		265.4
	Total	$	588.2	$	556.8
	See Notes 4 and 16 for further details regarding product recalls, customer sales allowances, customer accommodations and other related accruals.

PostRetirement_Obligations_and

Post-Retirement Obligations and Other Long-term Liabilities	9 Months Ended
	Sep. 30, 2014
Post-Retirement Obligations and Other Long-term Liabilities [Abstract]	'
Post-Retirement Obligations and Other Long-term Liabilities	'
	Post-Retirement Obligations and Other Long-term Liabilities
	Post-retirement obligations and other long-term liabilities consists of the following:
		September 30,		December 31,
	(dollars in millions)	2014		2013
	Accrued post-retirement medical and dental costs	$	48.3	$	48.3
	Pension liabilities	42.3		46.9
	Unrecognized tax benefits, including penalties and interest	44.3		45.7
	Product recalls, customer sales allowances, customer accommodations and other related accruals	36.6		103.7
	Accrued returns	12.2		10.3
	All other	31.7		46.8
	Total	$	215.4	$	301.7
	See Notes 4 and 16 for further details regarding product recalls, customer sales allowances, customer accommodations and other related accruals.

Product_Recalls_Customer_Sales

Product Recalls, Customer Sales Allowances, Customer Accommodations and Other Related Accruals	9 Months Ended
	Sep. 30, 2014
Payables and Accruals [Abstract]	'
Product Recalls and Other Related Accruals	'
	Product Recalls, Customer Sales Allowances, Customer Accommodations and Other Related Accruals
	Accruals for various product recalls, customer sales allowances, customer accommodations and other related accruals were $177.9 million and $214.2 million as of September 30, 2014 and December 31, 2013, respectively, and the current and long-term portions are reported in Other accrued liabilities and Post-retirement obligations and other long-term liabilities on the condensed consolidated balance sheets, respectively. Customer sales allowance charges are recognized in Net sales, while charges associated with product recalls, customer accommodations, and other related costs are recognized in Cost of products sold.
	The following summarizes product recalls, customer sales allowances, customer accommodations and other related accrual activity for the nine months ended September 30, 2014:
	(dollars in millions)
	Balances at January 1, 2014	$	214.2
	Provisions net of releases of prior provisions	5.5
	Payments	(41.8		)
	Balances at September 30, 2014	$	177.9

Pension_and_PostRetirement_Ben

Pension and Post-Retirement Benefits	9 Months Ended
	Sep. 30, 2014
Compensation and Retirement Disclosure [Abstract]	'
Pension and Post-Retirement Benefits	'
	Pension and Other Post-Retirement Benefits
	Hospira's retirement plans consist of defined benefit and legislated obligations such as employee severance indemnity plans ("pension plans"), post-retirement medical and dental plans ("medical and dental plans") and defined contribution plans. Plans cover certain employees both in and outside of the U.S.
	Net periodic benefit cost recognized for Hospira's pension and medical and dental plans consists of the following:
		Pension Plans
		Three Months Ended September 30,						Nine Months Ended September 30,
	(dollars in millions)	2014			2013			2014			2013
	Service cost for benefits earned during the period	$	0.4		$	0.4		$	1.3		$	1.1
	Interest cost on projected benefit obligations	6.5			5.9			19.5			17.7
	Expected return on plans' assets	(7.8		)	(7.8		)	(23.4		)	(23.5		)
	Amortization of net actuarial losses	3.1			4.7			9.3			14.3
	Net periodic benefit cost	$	2.2		$	3.2		$	6.7		$	9.6
		Medical and Dental Plans
		Three Months Ended September 30,						Nine Months Ended September 30,
	(dollars in millions)	2014			2013			2014			2013
	Service cost for benefits earned during the period	$	—		$	0.1		$	0.1		$	0.2
	Interest cost on projected benefit obligations	0.6			0.5			1.8			1.5
	Amortization of net actuarial losses	0.1			0.1			0.3			0.3
	Net periodic benefit cost	$	0.7		$	0.7		$	2.2		$	2
	In the third quarter of 2014, Hospira offered certain terminated vested participants in a U.S. pension plan, the Abbott/Hospira Transitional Annuity Retirement Plan, the opportunity to receive a lump-sum payment equal to the present value of the participant's pension benefit. The election window was open through October 31, 2014, with cash payment from the plan assets expected to occur during the fourth quarter of 2014. If payments from plan assets exceed a threshold, a settlement loss would be incurred, which would be recognized as a reclassification from Other Comprehensive Loss to Net Income (Loss). Administrative processes are still ongoing; however, anticipated payments at this time are not expected to exceed this threshold.
	Hospira has no estimated U.S. minimum required contribution for 2014 to meet the funding rules of the Pension Protection Act of 2006, giving consideration to the Worker, Retiree, and Employer Recovery Act of 2008. While Hospira's funding policy requires contributions to its defined benefit plans equal to the amounts necessary to, at a minimum, satisfy the funding requirements as prescribed by Federal laws and regulations, Hospira also makes discretionary contributions when management deems it is prudent to do so. No contributions were made to the U.S. pension plan for the nine months ended 2014, nor does Hospira expect to make any discretionary cash contributions in 2014.
	Certain Hospira employees in the U.S. and Puerto Rico participate in the Hospira 401(k) Retirement Savings Plan. Hospira's expenses for this defined contribution plan for the three months ended September 30, 2014 and 2013 were $11.5 million and $11.0 million, respectively. For the nine months ended September 30, 2014 and 2013, these expenses were $33.0 million and $32.1 million, respectively.

Shortterm_Borrowings_and_Longt

Short-term Borrowings and Long-term Debt	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Short-term Borrowings and Long-term Debt	'
	Short-term Borrowings and Long-term Debt
	As of September 30, 2014, Hospira had a $1.0 billion unsecured revolving credit facility (the "Revolver") maturing in October 2016 with no amounts outstanding. Amounts borrowed under the Revolver, if any, are included in the leverage ratio covenant and may limit Hospira's availability for borrowings to less than $1.0 billion. The availability of funds is limited by financial covenants related to Hospira's debt and financial position, and as of September 30, 2014, Hospira had no limit on the availability under the Revolver.
	As of September 30, 2014, Hospira was in compliance with all financial covenants.
	In August 2013, Hospira issued, in a registered public offering, $350.0 million principal amount of 5.20% notes due on August 12, 2020 and $350.0 million principal amount of 5.80% notes due on August 12, 2023 ("2020 and 2023 Notes"). In September 2013, the net proceeds of the 2020 and 2023 Notes, after deducting approximately $2.1 million of bond discounts and underwriting fees of $6.1 million plus cash on-hand, were used to extinguish $400.0 million principal amount of 5.90% notes originally due June 2014, $250.0 million principal amount of 6.40% notes originally due May 2015 ("2014 and 2015 Notes"), accrued interest and a make-whole premium payment of $39.8 million. In aggregate, Hospira incurred $33.4 million in charges associated with the early extinguishment of the 2014 and 2015 Notes, which is reported in Other expense, net, in the three and nine months ended September 30, 2013. The early debt extinguishment charges included a make-whole premium, write-off of previously capitalized debt issuance costs, discounts and deferred gains on interest rate hedges.
	In August 2013, Hospira terminated the forward starting interest rate swaps, notional amount of $550 million, which had effectively fixed the benchmark interest rates upon entering into the transactions in July 2013 and up to the issuance of the 2020 and 2023 Notes. As a result of the swap terminations, Hospira paid $3.6 million, including interest. The corresponding loss will be deferred in Accumulated other comprehensive loss and amortized into Interest expense over the terms of the 2020 and 2023 notes, respectively.

Income_Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	Income Taxes
	Taxes on income reflect the estimated annual effective rates, excluding the effect of significant unusual items. The effective tax rates are less than the statutory U.S. federal income tax rate principally due to the benefit of tax exemptions, of varying durations, in certain non-U.S. taxing jurisdictions.
	Hospira remains subject to tax examinations, which are in various stages, in the following major tax-paying jurisdictions: for years 2006 forward in Italy, for years 2007 forward in Australia, for years 2009 forward in Canada and for years 2010 forward in the U.S. and United Kingdom. Hospira estimates that within the next twelve months a decrease of up to approximately $10 million in the balance of unrecognized tax benefits could occur as a result of audit settlements or statute of limitations expirations.

Shareholders_Equity

Shareholders' Equity	9 Months Ended
	Sep. 30, 2014
Stockholders' Equity Note [Abstract]	'
Shareholders' Equity	'
	Shareholders' Equity
	Common and Preferred Stock
	Hospira is authorized to issue 400.0 million shares of common stock, par value $0.01 per share, and 50.0 million shares of preferred stock, par value $0.01 per share. As of September 30, 2014 and December 31, 2013, 182.3 million and 179.1 million common shares were issued and 169.1 million and 166.0 million common shares were outstanding, respectively. As of those dates, no shares of preferred stock were issued and outstanding. During May 2014, shareholders approved an amendment to the Company's 2004 Long-Term Stock Incentive Plan, as further discussed in Note 23, to increase the maximum number of shares available for issuance under this Plan.
	Treasury Stock
	In April 2011, Hospira's Board of Directors authorized the repurchase of up to $1.0 billion of Hospira's common stock. Hospira may periodically repurchase additional shares under this authorization, the timing of which will depend on various factors such as cash generation from operations, cash expenditure required for other purposes, current stock price and other factors. No common stock repurchases were made during the nine months ended September 30, 2014.

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive (Loss), net of tax	9 Months Ended
	Sep. 30, 2014
Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]	'
Accumulated Other Comprehensive Loss, net of tax	'
	Accumulated Other Comprehensive Loss, Net of Tax
	Changes in Accumulated Other Comprehensive Loss, net of taxes consists of the following:
	(dollars in millions)		Cumulative Foreign Currency Translation Adjustments(1)			Cumulative Unrealized Retirement Plans Losses(2)			Cumulative Unrealized Gains (Losses) on Investments(1)			Cumulative Losses on			Total Accumulated Other Comprehensive Loss
												Terminated Cash Flow Hedges(3)
	Balance at January 1, 2014		$	(98.4	)	$	(103.4	)	$	1.5		$	(1.7	)	$	(202.0	)
	Other comprehensive loss before reclassifications		(57.6		)	—			(2.1		)	—			(59.7		)
	Amounts reclassified from accumulated other comprehensive loss		—			5.9			—			0.1			6
	Balance at September 30, 2014		$	(156.0	)	$	(97.5	)	$	(0.6	)	$	(1.6	)	$	(255.7	)
	(1)	Net of taxes of $0.0 million as of September 30, 2014 and December 31, 2013.
	(2)	Net of taxes of $58.3 million and $62.0 million as of September 30, 2014 and December 31, 2013, respectively.
	(3)	Net of taxes of $1.1 million as of September 30, 2014 and December 31, 2013.
	The following summarizes reclassifications out of Accumulated Other Comprehensive Loss:
			Amounts Reclassified from
			Accumulated Other Comprehensive Loss
			Three Months Ended September 30,						Nine Months Ended September 30,
	(dollars in millions)		2014			2013			2014			2013			Line Item in the
															Condensed Consolidated
															Statement of Income (Loss)
	Impairment on investments		$	—		$	0.4		$	—		$	3.5		Other expense, net
			—			—			—			—			Income tax expense (benefit)
	Net of income taxes		—			0.4			—			3.5
	Amortization of loss on terminated cash flow hedges		—			(0.1		)	0.1			(0.2		)	Other expense, net
			—			—			—			—			Income tax expense (benefit)
	Net of income taxes		—			(0.1		)	0.1			(0.2		)
	Amortization of pension plans actuarial losses		3.1			4.7			9.3			14.3			(1)
	Amortization of medical and dental plans actuarial losses		0.1			0.1			0.3			0.3			(1)
	Total amortization before income taxes		3.2			4.8			9.6			14.6
			(1.1		)	(1.9		)	(3.7		)	(5.6		)	Income tax expense (benefit)
	Net of income taxes		2.1			2.9			5.9			9
	Total reclassifications for the period		$	2.1		$	3.2		$	6		$	12.3
	(1)	These components are included in the computation of net periodic benefit cost. See Note 17 for additional details.

Earnings_per_Share

Earnings per Share	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Earnings (Loss) per Share	'
	Earnings (Loss) Per Share
	Basic Earnings (Loss) Per Share is computed by dividing Net Income (Loss) by the number of weighted average common shares outstanding during the reporting period. Diluted Earnings (Loss) Per Share is calculated to give effect to all potentially dilutive common shares that were outstanding during each respective reporting period, in which such effect was dilutive. The following table shows the effect of stock-based awards on the weighted average number of shares outstanding used in calculating Diluted Earnings (Loss) Per Share, and the number of shares excluded from the Diluted Earnings (Loss) Per Share calculation as the exercise price of the awards exceeded the average stock price:
		Three Months Ended September 30,		Nine Months Ended September 30,
	(shares in millions)	2014	2013	2014	2013
	Weighted average basic common shares outstanding	168.9	165.7	167.7	165.5
	Incremental shares outstanding related to stock-based awards	2.9	1.3	2.5	—
	Weighted average dilutive common shares outstanding	171.8	167	170.2	165.5
	Outstanding awards for which the exercise price of the award exceeds the average stock price	0.3	8.2	3.7	8.5
	For the nine months ended September 30, 2013, 1.0 million incremental shares related to stock-based awards were not included in the computation of Diluted Earnings (Loss) Per Share due to the net loss for that period.

Incentive_Stock_Program

Incentive Stock Program	9 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Incentive Stock Program	'
	Incentive Stock Program
	Hospira's 2004 Long-Term Stock Incentive Plan ("2004 Plan"), as amended, provides for the grant of shares of stock options, stock appreciation rights, stock awards (restricted stock, restricted stock units, performance shares and performance units) and cash-based awards to employees and non-employee directors. In May 2014, shareholders approved an amendment to the 2004 Plan primarily to extend the term by 10 years to May 7, 2024, and to increase the number of shares that may be granted during the life of the 2004 Plan by an additional 10,000,000 shares. Stock-based compensation expense associated with Hospira's 2004 Plan consists of the following:
		Three Months Ended September 30,						Nine Months Ended September 30,
	(dollars in millions)	2014			2013			2014			2013
	Stock-based compensation expense	$	11.6		$	10.4		$	40.3		$	31.1
	Income tax benefit recognized	4.2			3.8			14.7			11.4
	As of September 30, 2014, there was $87.6 million of total unrecognized compensation costs related to non-vested share-based compensation arrangements. This cost is expected to be recognized over a weighted average period of 2.1 years.
	Stock Options
	During the nine months ended September 30, 2014, 1.4 million options were granted to certain employees primarily as part of the 2014 annual grant. These options were awarded at the fair market value at the time of grant, generally vest over four years and have a seven-year term. The expected life assumption of the options is based on the expected amount of time that options granted are expected to be outstanding, based on historical and forecasted exercise behavior of employees' post-vesting forfeitures and exercises.
	The weighted average grant date fair value using the Black-Scholes option-pricing model, and the corresponding weighted average assumptions for stock option grants, were as follows:
		Three Months Ended September 30,						Nine Months Ended September 30,
		2014			2013			2014			2013
	Expected volatility	27.7		%	31.5		%	27.7		%	30.3		%
	Expected life (years)	4.7			5.1			4.7			5.1
	Risk-free interest rate	1.7		%	1.3		%	1.5		%	0.9		%
	Expected dividend yield	0		%	0		%	0		%	0		%
	Fair value per stock option	$	13.94		$	11.77		$	11.37		$	8.48
	Performance Share Awards
	During the nine months ended September 30, 2014, 0.1 million performance share awards were granted to key members of management primarily as part of the 2014 annual grant. These awards vest at the end of a three-year performance cycle. The amount of awards is earned based on a formula measuring performance using relative total shareholder return over a three-year performance cycle compared to an industry peer group. Based on the actual performance at the end of the three-year performance cycle period, the number of performance share awards earned, which can range between 0% and 200% of the target awards granted, will be satisfied with Hospira common stock.
	The weighted average grant date fair value using the Monte Carlo simulation model and the corresponding weighted average assumptions for the annual performance share award grants, were as follows:
		Nine Months Ended September 30,
		2014			2013
	Expected volatility	30.8		%	30.8		%
	Risk-free interest rate	0.6		%	0.4		%
	Expected dividend yield	0		%	0		%
	Fair value per performance share	$	54.14		$	29.46
	Restricted Stock Units
	During the nine months ended September 30, 2014, 0.9 million restricted stock units ("restricted awards") were granted to certain employees and non-employee directors primarily as part of the 2014 annual grant. Hospira issues restricted awards with a vesting period ranging from one to three years. The weighted average grant date fair value of restricted awards granted for the nine months ended September 30, 2014 was $43.65 per restricted award. The weighted average grant date fair value for the nine months ended September 30, 2013 was $29.53 per restricted award.

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2014
Loss Contingency, Information about Litigation Matters [Abstract]	'
Commitments and Contingencies	'
	Commitments and Contingencies
	Hospira is involved in various claims and legal proceedings, as well as product liability claims, regulatory matters and proceedings related to Hospira's business, including in some instances when Hospira operated as part of Abbott Laboratories.
	Precedex™ Matters
	Hospira is involved in a number of lawsuits relating to the ability of various competitors to market a generic form of Hospira's Precedex™ (dexmedetomidine hydrochloride), a proprietary sedation agent.
	On January 15, 2014, the FDA opened a public docket to solicit comment from potential generic competitors for Precedex™ concentrate regarding the ability of those competitors to "carve-out" labeled indications and potentially achieve final product approval at any time. On August 18, 2014, the FDA allowed a carved-out label. Immediately following that decision, Mylan Institutional, LLC ("Mylan") and Par Sterile Products, LLC ("Par") launched generic versions of Precedex™ concentrate. On August 19, 2014, Hospira commenced action in the U.S. District Court for Maryland against the FDA (Sylvia Mathews Burwell, Secretary, U.S. Department of Health and Human Services and Dr. Margaret Hamburg, Commissioner, U.S. Food and Drug Administration) requesting, among other relief, a temporary restraining order. Mylan and Par intervened. Although a temporary restraining order was granted initially, the Court ruled in favor of the FDA on September 5, 2014, and Mylan and Par resumed their generic sales. On September 5, 2014, Hospira appealed to the U.S. Court of Appeals for the Fourth Circuit. On October 29, 2014, the Fourth Circuit Court dismissed the appeal, as the parties to the litigation entered into a settlement agreement on October 28, 2014. Pursuant to that settlement agreement, Mylan and Par may continue their generic sales under a carved-out label until near the end of the first quarter of 2015, after which those sales may continue with either the carved-out label or a full label.
	On August 25, 2014, Par filed a declaratory judgment action in the U.S. District Court for the District of New Jersey, Case 3:14-cv-05343-MLC-TJB seeking, inter alia, a finding of non-infringement and invalidity of U.S. Patent No. 6,716,867 (the "867 patent") (expires March 31, 2019), as well as injunctive and monetary relief against Hospira for violations of Section 2 of the Sherman Act, 15 U.S.C. § 2. This litigation was settled and dismissed as part of the settlement of the litigation discussed in the previous paragraph.
	In December 2013, Hospira entered into a settlement agreement in its patent infringement litigation over Precedex™ with Sandoz, Inc. and Sandoz Canada, Inc. (collectively "Sandoz"), related to Sandoz's "Paragraph IV" notice indicating that it has filed an abbreviated new drug application ("ANDA") with the FDA for a generic version of Precedex™. On September 22, 2014, the settlement agreement was amended to allow Sandoz to launch a generic version of Precedex™ in the U.S. from that date and Sandoz immediately launched a generic version of Precedex™ in the U.S.
	Hospira and Orion Corporation have brought suit in separate actions against the following parties alleging infringement of the 867 patent:
	Defendant	U.S. District Court Where Filed*
	Caraco Pharmaceutical Laboratories, Ltd.	Eastern District of Michigan, No. 10-cv-14514
	Akorn, Inc.	Northern District of Illinois, No. 14-cv-02811
	Actavis US Holding LLC and Actavis LLC	District of Delaware, No. 14-cv-00488
	Ben Venue Laboratories, Inc. d/b/a Bedford Laboratories	District of Delaware, No. 14-cv-00487
	Aurobindo Pharma Ltd. and Aurobindo Pharma USA, Inc.	District of Delaware, No. 14-cv-00486
	Intas Pharmaceuticals Ltd. and Accord Healthcare, Inc. USA	Middle District of North Carolina, No. 14-cv-00336
	*All filed April 18, 2014, except Caraco Pharmaceutical Laboratories, Ltd., which was filed November 12, 2010.
	The lawsuits are based on the "Paragraph IV" notice provided by the respective ANDA holders, above, indicating that each has filed an ANDA with the FDA for a generic version of Precedex™. Hospira seeks a judgment of infringement, injunctive relief and costs. Intas Pharmaceuticals Ltd. and Accord Healthcare, Inc. have notified Hospira that they converted their Paragraph IV certification to a "little viii" indicating an amendment to their label to carve out an indication. Caraco's ANDA has received tentative approval from the FDA.
	On June 20, 2014, Hospira received another "Paragraph IV" notice from Bedford Laboratories referencing Hospira's patents for Precedex™, including patents covering the pre-mix formulation of Precedex™. On August 1, 2014, Hospira brought suit against Ben Venue Laboratories, Inc. formerly d/b/a Bedford Laboratories, Hikma Pharmaceuticals Plc, and West-Ward Pharmaceutical Corp. in the District of Delaware, Case No. 14-cv-01008 seeking a judgment of infringement, injunctive relief and costs.
	Securities Litigation
	On September 5, 2014, the U.S. District Court for the Northern District of Illinois approved a settlement and dismissed a class action lawsuit filed against Hospira and certain of its current and former corporate officers alleging violations of the Securities and Exchange Act of 1934. In City of Sterling Heights General Employees' Retirement System, Individually and on behalf of all others similarly situated vs. Hospira, Inc., F. Michael Ball, Thomas E. Werner, James H. Hardy, Jr., and Christopher B. Begley, amended complaint filed June 25, 2012, the plaintiffs alleged, generally, that the defendants issued materially false and misleading statements regarding Hospira's financials and business prospects and failed to disclose material facts affecting Hospira's financial condition. The settlement was fully funded by insurance proceeds.
	Derivative Securities Litigation
	The parties have reached a tentative agreement to settle, subject to the Court's review and approval, two shareholder derivative lawsuits, which name as defendants certain current and former Hospira officers, and members of Hospira's Board of Directors. The first case, which consolidated two lawsuits filed in the United States District Court for the Northern District of Illinois in December 2011, is: Lori Ravenscroft Geare and Robert J. Casey, II, Derivatively for the Benefit of Hospira, Inc. v. Christopher B. Begley, F. Michael Ball, Thomas E. Werner, Irving W. Bailey, II, Jacque J. Sokolov, Barbara L. Bowles, Roger W. Hale, John C. Staley, Connie R. Curran, Heino von Prondzynski, Mark F. Wheeler, Terrence C. Kearney, Ronald A. Matricaria and Brian J. Smith and Hospira, Inc. (Nominal Defendant). The second case, filed in June 2014 in Delaware Chancery Court, is: International Union of Operating Engineers Pension Plan of Eastern Pennsylvania and Delaware v. Christopher B. Begley, F. Michael Ball, Thomas E. Werner, Irving W. Bailey, II, Jacque J. Sokolov, Barbara L. Bowles, Roger W. Hale, John C. Staley, Connie R. Curran, Heino von Prondzynski, Mark F. Wheeler, Terrence C. Kearney, and Ronald A. Matricaria and Hospira, Inc. (Nominal Defendant). In general terms, both lawsuits allege breaches of fiduciary duties by the individual defendants and seek damages, purportedly on behalf of Hospira, in connection with the matters covered by the securities lawsuit described under "Securities Litigation" above. It is anticipated that the settlement will be fully funded by insurance proceeds.
	Regulatory Matters
	Hospira's businesses are subject to regulatory inspections by regulatory authorities across the globe. Such regulatory inspections may lead to observations (commonly referred to as Form 483 observations in the U.S.), untitled letters, warning letters or similar correspondence, voluntary or involuntary product recalls, consent decrees, injunctions to halt manufacture and distribution of products, seizures of violative products, import and export bans or restrictions, monetary sanctions, delays in product approvals, civil penalties, criminal prosecution and other restrictions on operations.
	Hospira has received warning letters from the FDA related to matters affecting its pharmaceutical manufacturing facility in Mulgrave, Victoria, Australia, pharmaceutical and device manufacturing facilities in Clayton and Rocky Mount, North Carolina, its device manufacturing facility in La Aurora de Heredia, Costa Rica, Irungattukottai, India, and its device quality systems and governance in Lake Forest, Illinois. The Company has responded fully, and in a timely manner, to these warning letters. The remediation plans involve commitments by Hospira to enhance its quality system, products, facilities, employee training, quality processes and procedures, and technology. While Hospira continues implementing its remediation plans, the plans are subject to update and revision based on issues encountered by Hospira or its third-party consultants during the remediation process, or on further interaction with the FDA or other regulatory bodies. Hospira cannot, however, give any assurances as to the expected date of resolution of the matters identified in the warning letters.
	Litigation Exposure Evaluation
	Hospira's litigation exposure, including product liability claims, is evaluated each reporting period. Hospira's accruals, which are not significant at September 30, 2014 and December 31, 2013, are the best estimate of loss. Based upon information that is currently available, management believes that the likelihood of a material loss in excess of recorded amounts is remote.
	Additional legal proceedings may occur that may result in a change in the estimated accruals recorded by Hospira. It is not feasible to predict the outcome of such proceedings with certainty and there can be no assurance that their ultimate disposition will not have a material adverse effect on Hospira's financial position, cash flows, or results of operations.

Segment_Information

Segment Information	9 Months Ended
	Sep. 30, 2014
Segment Reporting, Disclosure of Other Information about Entity's Reportable Segments [Abstract]	'
Segment Information	'
	Segment Information
	Hospira conducts operations worldwide and is managed in three reportable segments: Americas, EMEA and APAC. The Americas reportable segment includes three operating segments, the U.S., Canada and Latin America; the EMEA reportable segment includes one operating segment, Europe, the Middle East and Africa; and the APAC reportable segment includes two operating segments, Asia & Japan and Australia & New Zealand. In all segments, Hospira sells a broad line of products, including Specialty Injectable Pharmaceuticals, Medication Management and Other Pharmaceuticals. Specialty Injectable Pharmaceuticals include generic injectables, proprietary specialty injectables and, in certain markets, biosimilars. Medication Management includes infusion pumps, related software and services, dedicated administration sets, gravity administration sets and other device products. Other Pharmaceuticals include large volume intravenous solutions, nutritionals and contract manufacturing.
	Hospira's underlying accounting records are maintained on a legal-entity basis for government and public reporting requirements. Segment disclosures are on a performance basis consistent with internal management reporting. For internal management reporting, intersegment transfers of inventory are recorded at standard cost and are not a measure of segment income from operations. The costs of certain corporate functions, stock-based compensation, Interest expense and Other expense, net that benefit the entire organization are not allocated. The following segment information has been prepared in accordance with the internal accounting policies of Hospira, as described in Note 1 of Notes to Consolidated Financial Statements in Item 8, Financial Statements and Supplementary Data, of Hospira's 2013 Form 10-K.
	Reportable segment information:
	The table below presents information about Hospira's reportable segments for the three months ended September 30:
		Net Sales				Income From Operations
	(dollars in millions)	2014		2013		2014			2013
	Americas	$	939	$	804.2	$	277.1		$	75.7
	EMEA	135.1		123.5		(15.0		)	(14.5		)
	APAC	76.5		80.5		2.4			(1.5		)
	Total reportable segments	$	1,150.60	$	1,008.20	264.5			59.7
	Corporate functions					(25.4		)	(19.5		)
	Stock-based compensation					(11.6		)	(10.4		)
	Income From Operations					227.5			29.8
	Interest expense and Other expense, net					(23.5		)	(62.3		)
	Income (Loss) Before Income Taxes					$	204		$	(32.5	)
	The table below presents information about Hospira's reportable segments for the nine months ended September 30:
		Net Sales				Income (Loss) From Operations
	(dollars in millions)	2014		2013		2014			2013
	Americas	$	2,694.00	$	2,318.90	$	557.7		$	147.5
	EMEA	400.5		369.9		(40.8		)	(73.5		)
	APAC	242.7		229.6		15.5			(16.7		)
	Total reportable segments	$	3,337.20	$	2,918.40	532.4			57.3
	Corporate functions					(65.5		)	(62.8		)
	Stock-based compensation					(40.3		)	(31.1		)
	Income (Loss) From Operations					426.6			(36.6		)
	Interest expense and Other expense, net					(60.3		)	(114.1		)
	Income (Loss) Before Income Taxes					$	366.3		$	(150.7	)
	Net sales and Income (Loss) From Operations for the nine months ended September 30, 2013 includes charges of $104.3 million, including $88.4 million in the Americas segment, $13.2 million in the EMEA segment and $2.7 million in the APAC segment related to the Device Strategy. See Note 4 for further information.

Basis_of_Presentation_and_Sign1

Basis of Presentation and Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2014
Basis of Presentation and Significant Accounting Policies [Abstract]	'
Supplier Advances	'
	Supplier Advances
	Hospira has outstanding advances, net of inventory receipts, of $50.5 million to Celltrion, Inc. and Celltrion Healthcare, Co., Ltd. (collectively "Celltrion") through September 30, 2014 for the purchase of certain biosimilar products. Additional supplier advances in the aggregate of $25.0 million for these biosimilar products may be required over the next two years, the timing of which is based on estimated regulatory approval dates and commercial launch dates. Hospira may distribute and market additional products sourced from Celltrion which would require additional advances.
	Total supplier advances were $54.9 million and $102.2 million as of September 30, 2014 and December 31, 2013, respectively. A portion of the decrease in supplier advances relates to the acquisition of Orchid Chemicals & Pharmaceuticals Ltd.'s ("Orchid") penem and penicillin Active Pharmaceutical Ingredient ("API") business, as further described in Note 2. The current and long-term portions are reported in Prepaid expenses and Other assets, respectively, in the condensed consolidated balance sheets. Supplier advances are in some cases long-term, refundable under certain conditions, either interest bearing or interest free, primarily unsecured and subject to credit risk.
Unapproved Products	'
	Unapproved Products
	Hospira capitalizes product costs, material and conversion costs in preparation for product launches prior to regulatory approval when regulatory approval of the products is considered probable.

Business_Acquisition_Business_

Business Acquisition Business Acquisition (Tables)	9 Months Ended
	Sep. 30, 2014
Business Combinations [Abstract]	'
Schedule of acquisition and integration-related costs	'
	The following summarizes acquisition and integration-related costs:
	(dollars in millions)		Three Months Ended September 30,				Nine Months Ended September 30,
			2014		2013		2014		2013
	Cost of products sold		$	1.9	$	—	$	1.9	$	—
	Selling, general and administrative		24.8		1.2		27.6		3.9
	Total		$	26.7	$	1.2	$	29.5	$	3.9
Schedule of recognized identified assets acquired and liabilities assumed	'
	The following table summarizes the fair value of the assets acquired and liabilities assumed, based on management's best estimate:
	(dollars in millions)
	Current assets, net	$	53.5
	Property and equipment	120.1
	Intangible assets (product rights)	18
	IPR&D	13
	Goodwill	48.7
	Other non-current assets and liabilities, net	(6.1		)
	Total allocation of purchase price	$	247.2

Restructuring_Actions_Tables

Restructuring Actions (Tables)	9 Months Ended
	Sep. 30, 2014
Restructuring and Related Activities [Abstract]	'
Aggregate restructuring activity	'
	The following summarizes the aggregate restructuring activity for the nine months ended September 30, 2014:
	(dollars in millions)	Employee-Related			Other			Total
		Benefit Costs
	Balance at January 1, 2014	$	2.5		$	1.8		$	4.3
	Costs (releases)	2.2			(0.8		)	1.4
	Payments	(2.9		)	(0.4		)	(3.3		)
	Balance at September 30, 2014	$	1.8		$	0.6		$	2.4

Device_Strategy_Tables

Device Strategy (Tables)	9 Months Ended
	Sep. 30, 2014
Device Strategy [Abstract]	'
Schedule of Device Strategy and Related Costs	'
	Charges incurred for the Device Strategy, primarily in the Americas segment, were reported as follows:
		Three Months Ended September 30,				Nine Months Ended September 30,				Line Item in the
										Condensed Consolidated
	(dollars in millions)	2014		2013		2014		2013		Statement of Income (Loss)
	Customer sales allowances	$	—	$	—	$	—	$	104.3	Net sales
	Consulting, customer accommodations, contract termination, collection and destruction and other costs	2.7		14.8		12.3		56.1		Cost of products sold
	Inventory charges	0.6		0.9		3		46.7		Cost of products sold
	Other asset impairments and accelerated depreciation	—		3.2		1.3		10.3		Restructuring, impairment and (gain) on disposal of assets, net
	Total charges	$	3.3	$	18.9	$	16.6	$	217.4

Investments_Tables

Investments (Tables)	9 Months Ended
	Sep. 30, 2014
Investments [Abstract]	'
Schedule of combined income statement financial information of unconsolidated equity method investments	'
	Combined income statement financial information of unconsolidated equity method investments is as follows:
		Nine Months Ended September 30,
	(dollars in millions)	2014		2013
	Revenue	$	47.3	$	69.9
	Operating expenses	27.3		33.3
	Operating income	20		36.6
	Net Income	24.2		28.9

Fair_Value_Measures_Tables

Fair Value Measures (Tables)	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Basis used to measure certain assets and liabilities at fair value	'
	The following table summarizes the methodology used to measure certain assets and liabilities at fair value on a recurring basis in the condensed consolidated balance sheets:
				Fair Value Measurements at Reporting Date, Using:
				Quoted Prices		Significant
				in Active Markets for		Other
				Identical Items		Observable
		September 30,				Inputs		Significant
								Unobservable
								Inputs
	(dollars in millions)	2014		(Level 1)		(Level 2)		(Level 3)
	Financial Assets:
	Foreign currency exchange contracts	$	7.6	$	7.6	$	—	$	—
	Investments	201.6		4.1		197.5		—
	Financial Liabilities:
	Foreign currency exchange contracts	1.4		—		1.4		—
	See Note 6 for additional information on the Level 2 investment.
				Fair Value Measurements at Reporting Date, Using:
				Quoted Prices		Significant
				in Active Markets for		Other
				Identical Items		Observable
		December 31,				Inputs		Significant
								Unobservable
								Inputs
	(dollars in millions)	2013		(Level 1)		(Level 2)		(Level 3)
	Financial Assets:
	Foreign currency exchange contracts	$	2.8	$	—	$	2.8	$	—
	Investments	3.8		3.8		—		—
	Financial Liabilities:
	Foreign currency exchange contracts	0.1		—		0.1		—
Carrying value and fair value of the senior unsecured notes	'
	The carrying value and estimated aggregate fair value, based primarily on market prices (Level 1), of the senior unsecured notes are as follows:
		September 30, 2014				December 31, 2013
	(dollars in millions)	Carrying		Fair Value		Carrying		Fair Value
		Value				Value
	Senior unsecured notes	$	1,750.00	$	1,887.70	$	1,750.00	$	1,794.80

Financial_Instruments_and_Deri1

Financial Instruments and Derivatives (Tables)	9 Months Ended
	Sep. 30, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Fair value of outstanding derivatives	'
	The following table summarizes Hospira's fair value of outstanding derivatives:
		Condensed Consolidated Balance	September 30,			December 31,
	(dollars in millions)	Sheet Presentation	2014			2013
	Derivatives not designated as hedging instruments
	Foreign currency exchange contracts:	Other receivables	$	7.6		$	2.8
		Other accrued liabilities	1.4			0.1
Impact on earnings from derivatives activity	'
	The impact on earnings from derivatives activity was as follows:
		Presentation of (Gain) Loss	Three Months Ended September 30,						Nine Months Ended September 30,
	(dollars in millions)	Recognized on Derivatives	2014			2013			2014			2013
	Derivatives not designated as hedging instruments
	Foreign currency exchange contracts	Other expense, net	$	(5.6	)	$	(3.0	)	$	(4.8	)	$	—

Inventories_Tables

Inventories (Tables)	9 Months Ended
	Sep. 30, 2014
Inventory Disclosure [Abstract]	'
Schedule of Inventories	'
	Inventories, net consists of the following:
		September 30,		December 31,
	(dollars in millions)	2014		2013
	Finished products	$	513.4	$	442.3
	Work in process	358.5		294.1
	Materials	318.1		329.8
	Total	$	1,190.00	$	1,066.20

Property_and_equipment_net_Tab

Property and equipment, net (Tables)	9 Months Ended
	Sep. 30, 2014
Property, Plant and Equipment [Abstract]	'
Property and equipment, net	'
	Property and equipment, net consists of the following:
		September 30,			December 31,
	(dollars in millions)	2014			2013
	Property and equipment, at cost	$	3,563.40		$	3,286.20
	Accumulated depreciation	(1,775.7		)	(1,712.0		)
	Total property and equipment, net	$	1,787.70		$	1,574.20

Goodwill_and_Intangible_assets1

Goodwill and Intangible assets, net (Tables)	9 Months Ended
	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Summary of Goodwill and Intangible Assets, Net	'
	The following summarizes Goodwill and Intangible assets, net activity:
					Intangible
	(dollars in millions)	Goodwill			assets, net
	Balance at January 1, 2014	$	1,057.70		$	172.2
	Additions	55.8			39.9
	Amortization	—			(60.8		)
	Disposals	(17.6		)	(4.9		)
	Currency translation effect	(2.9		)	(1.3		)
	Balance at September 30, 2014	$	1,093.00		$	145.1
Schedule of intangible assets, net	'
	Intangible assets, net consists of the following:
		Gross Carrying Amount						Accumulated Amortization						Intangible assets, net
		September 30,			December 31,			September 30,			December 31,			September 30,		December 31,
	(dollars in millions)	2014			2013			2014			2013			2014		2013
	Product rights and other	$	568.8		$	562.6		$	(461.2	)	$	(422.9	)	$	107.6	$	139.7
	Customer relationships	7.7			11.9			(6.4		)	(7.8		)	1.3		4.1
	IPR&D	13.8			2.2			—			—			13.8		2.2
	Technology	39			48.9			(16.6		)	(22.7		)	22.4		26.2
	Total	$	629.3		$	625.6		$	(484.2	)	$	(453.4	)	$	145.1	$	172.2

Other_Assets_Tables

Other Assets (Tables)	9 Months Ended
	Sep. 30, 2014
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]	'
Schedule of Other assets	'
	Other assets consists of the following:
		September 30,		December 31,
	(dollars in millions)	2014		2013
	Supplier advances	$	29.1	$	59.8
	Net investment in sales-type leases, less current portion	13		19.9
	Unapproved products	32.6		—
	Non-current receivables	32.5		33
	All other	29.2		31.6
	Total	$	136.4	$	144.3

SalesType_Leases_Tables

Sales-Type Leases (Tables)	9 Months Ended
	Sep. 30, 2014
Leases [Abstract]	'
Net investment in sales-type leases	'
	The net investment in sales-type leases of certain medication management products consists of the following:
			September 30,			December 31,
	(dollars in millions)		2014			2013
	Minimum lease payments receivables		$	23.2		$	32.1
	Unearned interest income		(2.0		)	(3.3		)
	Net investment in sales-type leases		21.2			28.8
	Current portion (1)		(8.2		)	(8.9		)
	Net investment in sales-type leases, less current portion (1)		$	13		$	19.9
	(1)	The current and long-term portions are reported in Trade receivables and Other assets, respectively.

Other_Accrued_Liabilities_Tabl

Other Accrued Liabilities (Tables)	9 Months Ended
	Sep. 30, 2014
Payables and Accruals [Abstract]	'
Other Accrued Liabilities	'
	Other accrued liabilities consists of the following:
		September 30,		December 31,
	(dollars in millions)	2014		2013
	Accrued rebates	$	134.7	$	150.4
	Income taxes payable	35.2		10.4
	Product recalls, customer sales allowances, customer accommodations and other related accruals	141.3		110.5
	Accrued returns	28.4		20.1
	All other	248.6		265.4
	Total	$	588.2	$	556.8

PostRetirement_Obligations_and1

Post-Retirement Obligations and Other Long-term Liabilities (Tables)	9 Months Ended
	Sep. 30, 2014
Post-Retirement Obligations and Other Long-term Liabilities [Abstract]	'
Components of Post-Retirement Obligations and Other Long-Term Liabilities	'
	Post-retirement obligations and other long-term liabilities consists of the following:
		September 30,		December 31,
	(dollars in millions)	2014		2013
	Accrued post-retirement medical and dental costs	$	48.3	$	48.3
	Pension liabilities	42.3		46.9
	Unrecognized tax benefits, including penalties and interest	44.3		45.7
	Product recalls, customer sales allowances, customer accommodations and other related accruals	36.6		103.7
	Accrued returns	12.2		10.3
	All other	31.7		46.8
	Total	$	215.4	$	301.7

Product_Recalls_Customer_Sales1

Product Recalls, Customer Sales Allowances, Customer Accommodations and Other Related Accruals (Tables)	9 Months Ended
	Sep. 30, 2014
Payables and Accruals [Abstract]	'
Summary of product recalls and other related accrual activity	'
	The following summarizes product recalls, customer sales allowances, customer accommodations and other related accrual activity for the nine months ended September 30, 2014:
	(dollars in millions)
	Balances at January 1, 2014	$	214.2
	Provisions net of releases of prior provisions	5.5
	Payments	(41.8		)
	Balances at September 30, 2014	$	177.9

Pension_and_PostRetirement_Ben1

Pension and Post-Retirement Benefits (Tables)	9 Months Ended
	Sep. 30, 2014
Compensation and Retirement Disclosure [Abstract]	'
Net cost recognized	'
	Net periodic benefit cost recognized for Hospira's pension and medical and dental plans consists of the following:
		Pension Plans
		Three Months Ended September 30,						Nine Months Ended September 30,
	(dollars in millions)	2014			2013			2014			2013
	Service cost for benefits earned during the period	$	0.4		$	0.4		$	1.3		$	1.1
	Interest cost on projected benefit obligations	6.5			5.9			19.5			17.7
	Expected return on plans' assets	(7.8		)	(7.8		)	(23.4		)	(23.5		)
	Amortization of net actuarial losses	3.1			4.7			9.3			14.3
	Net periodic benefit cost	$	2.2		$	3.2		$	6.7		$	9.6
		Medical and Dental Plans
		Three Months Ended September 30,						Nine Months Ended September 30,
	(dollars in millions)	2014			2013			2014			2013
	Service cost for benefits earned during the period	$	—		$	0.1		$	0.1		$	0.2
	Interest cost on projected benefit obligations	0.6			0.5			1.8			1.5
	Amortization of net actuarial losses	0.1			0.1			0.3			0.3
	Net periodic benefit cost	$	0.7		$	0.7		$	2.2		$	2

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive (Loss) Income, net of tax (Tables)	9 Months Ended
	Sep. 30, 2014
Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]	'
Accumulated other comprehensive (loss) income, net of taxes	'
	Changes in Accumulated Other Comprehensive Loss, net of taxes consists of the following:
	(dollars in millions)		Cumulative Foreign Currency Translation Adjustments(1)			Cumulative Unrealized Retirement Plans Losses(2)			Cumulative Unrealized Gains (Losses) on Investments(1)			Cumulative Losses on			Total Accumulated Other Comprehensive Loss
												Terminated Cash Flow Hedges(3)
	Balance at January 1, 2014		$	(98.4	)	$	(103.4	)	$	1.5		$	(1.7	)	$	(202.0	)
	Other comprehensive loss before reclassifications		(57.6		)	—			(2.1		)	—			(59.7		)
	Amounts reclassified from accumulated other comprehensive loss		—			5.9			—			0.1			6
	Balance at September 30, 2014		$	(156.0	)	$	(97.5	)	$	(0.6	)	$	(1.6	)	$	(255.7	)
	(1)	Net of taxes of $0.0 million as of September 30, 2014 and December 31, 2013.
	(2)	Net of taxes of $58.3 million and $62.0 million as of September 30, 2014 and December 31, 2013, respectively.
	(3)	Net of taxes of $1.1 million as of September 30, 2014 and December 31, 2013.
Schedule of reclassifications out of accumulated other comprehensive loss	'
	The following summarizes reclassifications out of Accumulated Other Comprehensive Loss:
			Amounts Reclassified from
			Accumulated Other Comprehensive Loss
			Three Months Ended September 30,						Nine Months Ended September 30,
	(dollars in millions)		2014			2013			2014			2013			Line Item in the
															Condensed Consolidated
															Statement of Income (Loss)
	Impairment on investments		$	—		$	0.4		$	—		$	3.5		Other expense, net
			—			—			—			—			Income tax expense (benefit)
	Net of income taxes		—			0.4			—			3.5
	Amortization of loss on terminated cash flow hedges		—			(0.1		)	0.1			(0.2		)	Other expense, net
			—			—			—			—			Income tax expense (benefit)
	Net of income taxes		—			(0.1		)	0.1			(0.2		)
	Amortization of pension plans actuarial losses		3.1			4.7			9.3			14.3			(1)
	Amortization of medical and dental plans actuarial losses		0.1			0.1			0.3			0.3			(1)
	Total amortization before income taxes		3.2			4.8			9.6			14.6
			(1.1		)	(1.9		)	(3.7		)	(5.6		)	Income tax expense (benefit)
	Net of income taxes		2.1			2.9			5.9			9
	Total reclassifications for the period		$	2.1		$	3.2		$	6		$	12.3
	(1)	These components are included in the computation of net periodic benefit cost. See Note 17 for additional details.

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Disclosure of basic and diluted earnings per share and effect of stock-based awards on the weighted average number of shares outstanding used in calculating diluted earnings per share	'
	The following table shows the effect of stock-based awards on the weighted average number of shares outstanding used in calculating Diluted Earnings (Loss) Per Share, and the number of shares excluded from the Diluted Earnings (Loss) Per Share calculation as the exercise price of the awards exceeded the average stock price:
		Three Months Ended September 30,		Nine Months Ended September 30,
	(shares in millions)	2014	2013	2014	2013
	Weighted average basic common shares outstanding	168.9	165.7	167.7	165.5
	Incremental shares outstanding related to stock-based awards	2.9	1.3	2.5	—
	Weighted average dilutive common shares outstanding	171.8	167	170.2	165.5
	Outstanding awards for which the exercise price of the award exceeds the average stock price	0.3	8.2	3.7	8.5

Incentive_Stock_Program_Tables

Incentive Stock Program (Tables)	9 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Share-based Compensation Expense	'
	Stock-based compensation expense associated with Hospira's 2004 Plan consists of the following:
		Three Months Ended September 30,						Nine Months Ended September 30,
	(dollars in millions)	2014			2013			2014			2013
	Stock-based compensation expense	$	11.6		$	10.4		$	40.3		$	31.1
	Income tax benefit recognized	4.2			3.8			14.7			11.4
Weighted average fair value and weighted average assumptions utilized for option grants	'
	The weighted average grant date fair value using the Black-Scholes option-pricing model, and the corresponding weighted average assumptions for stock option grants, were as follows:
		Three Months Ended September 30,						Nine Months Ended September 30,
		2014			2013			2014			2013
	Expected volatility	27.7		%	31.5		%	27.7		%	30.3		%
	Expected life (years)	4.7			5.1			4.7			5.1
	Risk-free interest rate	1.7		%	1.3		%	1.5		%	0.9		%
	Expected dividend yield	0		%	0		%	0		%	0		%
	Fair value per stock option	$	13.94		$	11.77		$	11.37		$	8.48
Weighted fair value and weighted average assumptions for the performance share award grants	'
	The weighted average grant date fair value using the Monte Carlo simulation model and the corresponding weighted average assumptions for the annual performance share award grants, were as follows:
		Nine Months Ended September 30,
		2014			2013
	Expected volatility	30.8		%	30.8		%
	Risk-free interest rate	0.6		%	0.4		%
	Expected dividend yield	0		%	0		%
	Fair value per performance share	$	54.14		$	29.46

Segment_Information_Tables

Segment Information (Tables)	9 Months Ended
	Sep. 30, 2014
Segment Reporting, Disclosure of Other Information about Entity's Reportable Segments [Abstract]	'
Information about Hospira's reportable segments	'
	The table below presents information about Hospira's reportable segments for the three months ended September 30:
		Net Sales				Income From Operations
	(dollars in millions)	2014		2013		2014			2013
	Americas	$	939	$	804.2	$	277.1		$	75.7
	EMEA	135.1		123.5		(15.0		)	(14.5		)
	APAC	76.5		80.5		2.4			(1.5		)
	Total reportable segments	$	1,150.60	$	1,008.20	264.5			59.7
	Corporate functions					(25.4		)	(19.5		)
	Stock-based compensation					(11.6		)	(10.4		)
	Income From Operations					227.5			29.8
	Interest expense and Other expense, net					(23.5		)	(62.3		)
	Income (Loss) Before Income Taxes					$	204		$	(32.5	)
	The table below presents information about Hospira's reportable segments for the nine months ended September 30:
		Net Sales				Income (Loss) From Operations
	(dollars in millions)	2014		2013		2014			2013
	Americas	$	2,694.00	$	2,318.90	$	557.7		$	147.5
	EMEA	400.5		369.9		(40.8		)	(73.5		)
	APAC	242.7		229.6		15.5			(16.7		)
	Total reportable segments	$	3,337.20	$	2,918.40	532.4			57.3
	Corporate functions					(65.5		)	(62.8		)
	Stock-based compensation					(40.3		)	(31.1		)
	Income (Loss) From Operations					426.6			(36.6		)
	Interest expense and Other expense, net					(60.3		)	(114.1		)
	Income (Loss) Before Income Taxes					$	366.3		$	(150.7	)

Basis_of_Presentation_and_Sign2

Basis of Presentation and Significant Accounting Policies (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014
In Millions, unless otherwise specified			Celltrion [Member]	Accounting Standards Update 2013-11 [Member]	Accounting Standards Update 2013-11 [Member]
Supplier Advances	'	'	'	'	'
Decrease in deferred income tax assets	'	'	'	'	$25
Decrease in post-retirement obligations and other long-term liabilities	'	'	'	25	'
Outstanding advances, net of inventory receipts	'	'	50.5	'	'
Additional supplier advances in the future period	'	'	25	'	'
Period for additional supplier advances	'	'	'2 years	'	'
Advances to supplier	54.9	102.2	'	'	'
Unapproved Products	42.8	7.1	'	'	'
Unapproved Product Reserves	$7	$2.30	'	'	'

Business_Acquisition_Details

Business Acquisition (Details) (USD $)

0 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

In Millions, unless otherwise specified

Jul. 04, 2014

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Jul. 04, 2014

Feb. 28, 2014

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

API Busines

API Busines

API Busines

API Busines

API Busines

API Busines

Evolabis

Cost of products sold

Cost of products sold

Cost of products sold

Cost of products sold

Selling, general and administrative

Selling, general and administrative

Selling, general and administrative

Selling, general and administrative

product

API Busines

API Busines

API Busines

API Busines

API Busines

API Busines

API Busines

API Busines

Business Acquisition [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preliminary purchase price

'

'

'

'

'

$247.20

'

'

'

'

'

'

'

'

'

Exchange rate impacts, working capital adjustments, assumption of debt and settlement

29.5

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Portion of purchase price, subject to eighteen month hold-back

17

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Acquisition and integration-related costs

'

26.7

1.2

29.5

3.9

'

'

1.9

0

1.9

0

24.8

1.2

27.6

3.9

Cumulative acquisition and integration-related costs

'

'

'

35.1

'

'

'

'

'

'

'

'

'

'

'

Advances to primary shareholder to pay legal and other fees

'

'

'

'

'

$17.30

'

'

'

'

'

'

'

'

'

Number of on-market oncology products added

'

'

'

'

'

'

15

'

'

'

'

'

'

'

'

Business_Acquisition_Assets_Ac

Business Acquisition (Assets Acquired and Liabilities Assumed) (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Jul. 04, 2014	Jul. 04, 2014
In Millions, unless otherwise specified			API Busines	Product Rights
				API Busines
Business Acquisition [Line Items]	'	'	'	'
Current assets, net	'	'	$53.50	'
Property and equipment	'	'	120.1	'
Intangible assets (product rights)	'	'	18	'
IPR&D	'	'	13	'
Goodwill	1,093	1,057.70	48.7	'
Other non-current assets and liabilities, net	'	'	-6.1	'
Total allocation of purchase price	'	'	$247.20	'
Weighted average useful life	'	'	'	'9 years

Restructuring_Actions_Details

Restructuring Actions (Details) (USD $)

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

In Millions, unless otherwise specified

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Aug. 31, 2014

Sep. 30, 2014

Sep. 30, 2014

Employee Severance

Contract Termination

Buffalo Manufacturing Facility

Surgical Product Line

Surgical Product Line

Surgical Product Line

TheraDoc, Inc.

TheraDoc, Inc.

installment

Restructuring Reserve

'

'

'

'

'

'

'

'

'

'

'

'

Restructuring costs incurred to date

'

'

'

'

$13.60

$2.30

'

'

'

'

'

'

Restructuring Charges

-0.6

3.1

1.4

7.6

'

'

'

'

'

'

'

'

Expected loss on disposal

'

'

'

'

'

'

5

'

'

'

'

'

Sale of a product line, consideration

'

'

'

'

'

'

'

'

'

21.5

117

117

Number of installments consideration is payable

'

'

'

'

'

'

'

'

'

3

'

'

Pre-tax gain recognized on sale of product line

'

'

'

'

'

'

'

$15.90

$15.90

'

$89.90

$89.90

Restructuring_Actions_Details_

Restructuring Actions (Details 2) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Restructuring Reserve [Roll Forward]	'	'	'	'
Balance at January 1, 2014	'	'	$4.30	'
Costs incurred	-0.6	3.1	1.4	7.6
Payments	'	'	-3.3	'
Balance at September 30, 2014	2.4	'	2.4	'
Employee-Related Benefit Costs	'	'	'	'
Restructuring Reserve [Roll Forward]	'	'	'	'
Balance at January 1, 2014	'	'	2.5	'
Costs incurred	'	'	2.2	'
Payments	'	'	-2.9	'
Balance at September 30, 2014	1.8	'	1.8	'
Other	'	'	'	'
Restructuring Reserve [Roll Forward]	'	'	'	'
Balance at January 1, 2014	'	'	1.8	'
Costs incurred	'	'	-0.8	'
Payments	'	'	-0.4	'
Balance at September 30, 2014	$0.60	'	$0.60	'

Device_Strategy_Details

Device Strategy (Details) (Device Strategy, USD $)

9 Months Ended

21 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

In Millions, unless otherwise specified

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2014

Net Sales

Net Sales

Net Sales

Net Sales

Net Sales

Cost of Products Sold

Cost of Products Sold

Cost of Products Sold

Cost of Products Sold

Cost of Products Sold

Cost of Products Sold

Cost of Products Sold

Cost of Products Sold

Restructuring and Impairment

Restructuring and Impairment

Restructuring and Impairment

Restructuring and Impairment

Americas

Americas

Americas

Americas

Americas

Minimum

Maximum

Customer sales allowances

Customer sales allowances

Customer sales allowances

Customer sales allowances

Consulting, customer accommodations, contract termination, collection and destruction and other costs

Consulting, customer accommodations, contract termination, collection and destruction and other costs

Consulting, customer accommodations, contract termination, collection and destruction and other costs

Consulting, customer accommodations, contract termination, collection and destruction and other costs

Inventory charges

Inventory charges

Inventory charges

Inventory charges

Other asset impairments and accelerated depreciation

Other asset impairments and accelerated depreciation

Other asset impairments and accelerated depreciation

Other asset impairments and accelerated depreciation

Net Sales

Device Strategy and Related Costs [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected costs in connection with the Device Strategy

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$300

$350

Estimated aggregate charges, cash

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

240

290

Expected non-cash charges

60

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Charges incurred

'

$243.50

$104.30

$0

$0

$0

$104.30

$2.70

$14.80

$12.30

$56.10

$0.60

$0.90

$3

$46.70

$0

$3.20

$1.30

$10.30

$3.30

$18.90

$16.60

$217.40

$88.40

'

'

Collaborative_Arrangements_Det

Collaborative Arrangements (Details) (USD $)

3 Months Ended

9 Months Ended

18 Months Ended

0 Months Ended

3 Months Ended

9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Apr. 29, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Apr. 29, 2013

Apr. 30, 2013

NovaQuest

NovaQuest

NovaQuest

NovaQuest

NovaQuest

NovaQuest

Maximum

product

NovaQuest

Schedule of Collaborative Arrangement Agreements [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Number of biosimilar products in an agreement

'

'

'

'

'

'

'

'

'

'

3

'

Development funding to be contributed

'

'

'

'

'

'

'

'

'

'

'

$120,000,000

Research and development expense

86,300,000

69,900,000

245,200,000

218,100,000

'

50,000,000

9,400,000

22,100,000

28,100,000

36,400,000

'

'

Cumulative development funding

'

'

'

'

$78,100,000

'

'

'

'

'

'

'

Investments_Details

Investments (Details) (USD $)

3 Months Ended

9 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Aug. 31, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Jul. 31, 2014

Sep. 30, 2014

Zydus Hospira Oncology Private Limited

Zydus Hospira Oncology Private Limited

Unconsolidated equity method investments

Unconsolidated equity method investments

Other expense, net

Other expense, net

R&D Venture

Convertible Bond Due September 30, 2019

Convertible Debt

Equity method investments

'

'

'

'

'

'

'

'

'

'

'

'

'

Face amount

'

'

'

'

$350,000,000

'

'

'

'

'

'

'

$200,000,000

Interest rate

'

'

'

'

'

'

'

'

'

'

'

'

6.00%

Ownership in a joint venture, Zydus Hospira Oncology Private Limited (as a percent)

'

'

'

'

'

50.00%

'

'

'

'

'

'

'

Equity income from affiliates, net

3,200,000

2,700,000

15,200,000

12,700,000

'

'

'

'

'

'

'

'

'

Distributions received from equity affiliates

'

'

16,300,000

30,100,000

'

16,300,000

30,100,000

'

'

'

'

'

'

Combined income statement information of unconsolidated equity method investments

'

'

'

'

'

'

'

'

'

'

'

'

'

Revenue

1,150,600,000

1,008,200,000

3,337,200,000

2,918,400,000

'

'

'

47,300,000

69,900,000

'

'

'

'

Operating expenses

'

'

'

'

'

'

'

27,300,000

33,300,000

'

'

'

'

Operating income

227,500,000

29,800,000

426,600,000

-36,600,000

'

'

'

20,000,000

36,600,000

'

'

'

'

Net Income

158,600,000

1,900,000

297,400,000

-41,800,000

'

'

'

24,200,000

28,900,000

'

'

'

'

Advances to affiliate

'

'

'

'

'

'

'

'

'

'

'

30,000,000

'

Additional advances within 12 months

'

'

'

'

'

'

'

'

'

'

'

15,000,000

'

Non-cash impairment charges to impair equity method investments

'

'

'

'

'

'

'

'

'

2,700,000

11,000,000

'

'

Impairment charges recognized in Other (income) expense

'

'

'

'

'

'

'

'

'

$400,000

$3,500,000

'

'

Fair_Value_Measures_Details

Fair Value Measures (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Fair Value Assets and Liabilities Measurement	'	'
Foreign currency exchange contracts	$7.60	$2.80
Investments	201.6	3.8
Foreign currency exchange contracts	1.4	0.1
Senior unsecured notes, carrying value	1,750	1,750
Senior unsecured notes, fair value	1,887.70	1,794.80
Quoted Prices in Active Markets for Identical Items (Level 1)	'	'
Fair Value Assets and Liabilities Measurement	'	'
Foreign currency exchange contracts	7.6	0
Investments	4.1	3.8
Foreign currency exchange contracts	0	0
Significant Other Observable Inputs (Level 2)	'	'
Fair Value Assets and Liabilities Measurement	'	'
Foreign currency exchange contracts	0	2.8
Investments	197.5	0
Foreign currency exchange contracts	1.4	0.1
Significant Unobservable Inputs (Level 3)	'	'
Fair Value Assets and Liabilities Measurement	'	'
Foreign currency exchange contracts	0	0
Investments	0	0
Foreign currency exchange contracts	$0	$0

Financial_Instruments_and_Deri2

Financial Instruments and Derivatives (Details) (Derivatives not designated as hedging instruments, Foreign currency forward exchange contracts, USD $)	Sep. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Other receivables	'	'
Derivatives, Fair Value	'	'
Derivative asset	$7.60	$2.80
Other accrued liabilities	'	'
Derivatives, Fair Value	'	'
Derivative liability	$1.40	$0.10

Financial_Instruments_and_Deri3

Financial Instruments and Derivatives (Details 2) (Derivatives not designated as hedging instruments, Foreign currency forward exchange contracts, Other expense, net, USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Derivatives not designated as hedging instruments | Foreign currency forward exchange contracts | Other expense, net	'	'	'	'
Derivative Instruments, Loss (Gain)	'	'	'	'
Presentation of (Gain) Loss Recognized on Derivatives	($5.60)	($3)	($4.80)	$0

Financial_Instruments_and_Deri4

Financial Instruments and Derivatives (Details 3) (Foreign Exchange Option, Designated as Hedging Instrument)	1 Months Ended
	Jun. 30, 2014	Jun. 30, 2014
	USD ($)	INR
Derivatives, Fair Value	'	'
Aggregate notional value of foreign currency exchange option contracts	'	10,000,000,000
Gain on derivative	$5,800,000	'

Inventories_Details

Inventories (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Inventory Disclosure [Abstract]	'	'
Finished products	$513.40	$442.30
Work in process	358.5	294.1
Materials	318.1	329.8
Total inventories	1,190	1,066.20
Inventor Reserves	$143.20	$143.30

Property_and_equipment_net_Det

Property and equipment, net (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Property, Plant and Equipment [Abstract]	'	'
Property and equipment, at cost	$3,563.40	$3,286.20
Less: accumulated depreciation	-1,775.70	-1,712
Total property and equipment, net	$1,787.70	$1,574.20

Goodwill_and_Intangible_assets2

Goodwill and Intangible assets, net (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Goodwill	'	'	'	'
Balance at January 1, 2014	'	'	$1,057.70	'
Additions	'	'	55.8	'
Disposals	'	'	-17.6	'
Currency translation effect	'	'	-2.9	'
Balance at September 30, 2014	1,093	'	1,093	'
Intangible assets, net	'	'	'	'
Balance at January 1, 2014	'	'	172.2	'
Additions	'	'	39.9	'
Amortization	-16.6	-20.5	-60.8	-63.8
Disposals	'	'	-4.9	'
Currency translation effect	'	'	-1.3	'
Balance at September 30, 2014	$145.10	'	$145.10	'

Goodwill_and_Intangible_assets3

Goodwill and Intangible assets, net (Details 2) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Intangible Assets:	'	'	'	'	'
Finite-lived intangible assets, amortization expense	$16.60	$20.50	$60.80	$63.80	'
Estimated intangible asset amortization for 2014	75	'	75	'	'
Estimated intangible asset amortization for 2015	47	'	47	'	'
Estimated intangible asset amortization for 2016	26	'	26	'	'
Estimated intangible asset amortization for 2017	16	'	16	'	'
Estimated intangible asset amortization for 2018	7	'	7	'	'
Gross Carrying Amount	629.3	'	629.3	'	625.6
Accumulated Amortization	-484.2	'	-484.2	'	-453.4
Net Intangible Assets	145.1	'	145.1	'	172.2
IPR&D	'	'	'	'	'
Intangible Assets:	'	'	'	'	'
Gross Carrying Amount	13.8	'	13.8	'	2.2
Accumulated Amortization	0	'	0	'	0
Net Intangible Assets	13.8	'	13.8	'	2.2
Product rights and other	'	'	'	'	'
Intangible Assets:	'	'	'	'	'
Gross Carrying Amount	568.8	'	568.8	'	562.6
Accumulated Amortization	-461.2	'	-461.2	'	-422.9
Net Intangible Assets	107.6	'	107.6	'	139.7
Customer relationships	'	'	'	'	'
Intangible Assets:	'	'	'	'	'
Gross Carrying Amount	7.7	'	7.7	'	11.9
Accumulated Amortization	-6.4	'	-6.4	'	-7.8
Net Intangible Assets	1.3	'	1.3	'	4.1
Technology	'	'	'	'	'
Intangible Assets:	'	'	'	'	'
Gross Carrying Amount	39	'	39	'	48.9
Accumulated Amortization	-16.6	'	-16.6	'	-22.7
Net Intangible Assets	$22.40	'	$22.40	'	$26.20
Minimum	'	'	'	'	'
Intangible Assets:	'	'	'	'	'
Useful lives of intangible assets (in years)	'	'	'1 year	'	'
Maximum	'	'	'	'	'
Intangible Assets:	'	'	'	'	'
Useful lives of intangible assets (in years)	'	'	'16 years	'	'
Weighted Average	'	'	'	'	'
Intangible Assets:	'	'	'	'	'
Useful lives of intangible assets (in years)	'	'	'10 years	'	'

Other_Assets_Details

Other Assets (Details) (USD $)	Sep. 30, 2014		Dec. 31, 2013
In Millions, unless otherwise specified
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]	'		'
Supplier advances	$29.10		$59.80
Net investment in sales-type leases, less current portion	13	[1]	19.9	[1]
Unapproved products	32.6		0
Non-current receivables	32.5		33
All other	29.2		31.6
Total	$136.40		$144.30
[1]	The current and long-term portions are reported in Trade receivables and Other assets, respectively.

SalesType_Leases_Details

Sales-Type Leases (Details) (USD $)	9 Months Ended		12 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014		Dec. 31, 2013
Net investment in sales-type leases	'		'
Minimum lease payments receivable	$23.20		$32.10
Unearned interest income	-2		-3.3
Net investment in sales-type leases	21.2		28.8
Current portion	-8.2	[1]	-8.9	[1]
Net investment in sales-type leases, less current portion	$13	[1]	$19.90	[1]
Number of days amount past due in sales-type leases	'90 days		'90 days
[1]	The current and long-term portions are reported in Trade receivables and Other assets, respectively.

Other_Accrued_Liabilities_Deta

Other Accrued Liabilities (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Payables and Accruals [Abstract]	'	'
Accrued rebates	$134.70	$150.40
Income taxes payable	35.2	10.4
Product recalls, customer sales allowances, customer accommodations and other related accruals	141.3	110.5
Accrued returns	28.4	20.1
All other	248.6	265.4
Total	$588.20	$556.80

PostRetirement_Obligations_and2

Post-Retirement Obligations and Other Long-term Liabilities (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Post-Retirement Obligations and Other Long-term Liabilities [Abstract]	'	'
Accrued post-retirement medical and dental costs	$48.30	$48.30
Pension liabilities	42.3	46.9
Unrecognized tax benefits, including penalties and interest	44.3	45.7
Product recalls, customer sales allowances, customer accommodations and other related accruals	36.6	103.7
Accrued returns	12.2	10.3
All other	31.7	46.8
Total	$215.40	$301.70

Product_Recalls_Customer_Sales2

Product Recalls, Customer Sales Allowances, Customer Accommodations and Other Related Accruals (Textual) (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Payables and Accruals [Abstract]	'	'
Product recall and other related accruals	$177.90	$214.20

Product_Recalls_Customer_Sales3

Product Recalls, Customer Sales Allowances, Customer Accommodations and Other Related Accruals (Details) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014
Product Recalls and Related Accruals [Roll Forward]	'
Balances at January 1, 2014	$214.20
Provisions net of releases of prior provisions	5.5
Payments	-41.8
Balances at September 30, 2014	$177.90

Pension_and_PostRetirement_Ben2

Pension and Post-Retirement Benefits (Details) (USD $)

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

In Millions, unless otherwise specified

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2014

Pension Plans

Pension Plans

Pension Plans

Pension Plans

Medical and Dental Plans

Medical and Dental Plans

Medical and Dental Plans

Medical and Dental Plans

Forecast

Medical and Dental Plans

Defined Benefit Plan Disclosure

'

'

'

'

'

'

'

'

'

'

'

'

'

Service cost for benefits earned during the period

'

'

'

'

$0.40

$0.40

$1.30

$1.10

$0

$0.10

$0.10

$0.20

'

Interest cost on projected benefit obligations

'

'

'

'

6.5

5.9

19.5

17.7

0.6

0.5

1.8

1.5

'

Expected return on plans' assets

'

'

'

'

-7.8

-7.8

-23.4

-23.5

'

'

'

'

'

Amortization of net actuarial losses

'

'

'

'

3.1

4.7

9.3

14.3

0.1

0.1

0.3

0.3

'

Net periodic benefit cost

'

'

'

'

2.2

3.2

6.7

9.6

0.7

0.7

2.2

2

'

Settlement charge, before tax

'

'

'

'

'

'

'

'

'

'

'

'

10

Defined contribution plan expenses

$11.50

$11

$33

$32.10

'

'

'

'

'

'

'

'

'

Shortterm_Borrowings_and_Longt1

Short-term Borrowings and Long-term Debt (Details) (USD $)	1 Months Ended	9 Months Ended
	Aug. 31, 2013	Sep. 30, 2014	Sep. 30, 2013
Long-term and Short-term Debt Instruments [Line Items]	'	'	'
Face amount	$350,000,000	'	'
Unamortized discount (premium), net	2,100,000	'	'
Payments of debt issuance costs	6,100,000	'	'
Payment on early debt extinguishment	'	0	39,800,000
Loss on early debt extinguishment	'	0	33,400,000
Senior Notes Due August 12, 2020 [Member]	'	'	'
Long-term and Short-term Debt Instruments [Line Items]	'	'	'
Face amount	350,000,000	'	'
Interest rate	5.20%	'	'
Senior Notes Due August 12, 2023 [Member]	'	'	'
Long-term and Short-term Debt Instruments [Line Items]	'	'	'
Interest rate	5.80%	'	'
Senior Notes Due June 2014 [Member]	'	'	'
Long-term and Short-term Debt Instruments [Line Items]	'	'	'
Interest rate	'	'	5.90%
Extinguishment of debt, amount	'	'	400,000,000
Senior Notes Due May 2015 [Member]	'	'	'
Long-term and Short-term Debt Instruments [Line Items]	'	'	'
Interest rate	'	'	6.40%
Extinguishment of debt, amount	'	'	250,000,000
Senior Notes 2014 and 2015 [Member]	'	'	'
Long-term and Short-term Debt Instruments [Line Items]	'	'	'
Payment on early debt extinguishment	'	'	39,800,000
Loss on early debt extinguishment	'	'	33,400,000
Unsecured Revolving Credit Facility Due October, 2016	'	'	'
Long-term and Short-term Debt Instruments [Line Items]	'	'	'
Maximum borrowing capacity	'	1,000,000,000	'
Interest Rate Swap [Member]	'	'	'
Long-term and Short-term Debt Instruments [Line Items]	'	'	'
Notional amount of derivative terminated	550,000,000	'	'
Swap termination charges and interest	$3,600,000	'	'

Income_Taxes_Details

Income Taxes (Details) (USD $)	9 Months Ended
	Sep. 30, 2014
Income Tax Disclosure [Abstract]	'
Unrecognized tax benefits, estimated future decreases resulting from settlements with taxing authorities in next fiscal year	$10,000,000

Shareholders_Equity_Details

Shareholders' Equity (Details) (USD $)	1 Months Ended	9 Months Ended
	Apr. 30, 2011	Sep. 30, 2014	Dec. 31, 2013
Common and Preferred Stock	'	'	'
Common stock authorized (shares)	'	400,000,000	'
Common stock par value (in dollars per share)	'	$0.01	'
Preferred stock authorized (shares)	'	50,000,000	'
Preferred stock par value (in dollars per share)	'	$0.01	'
Common stock issued (shares)	'	182,300,000	179,100,000
Common stock outstanding (shares)	'	169,100,000	166,000,000
Treasury Stock	'	'	'
Treasury Stock, repurchase authorization (in dollars)	$1,000,000,000	$0	'

Accumulated_Other_Comprehensiv2

Accumulated Other Comprehensive (Loss) Income, net of tax (Details) (USD $)	3 Months Ended				9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014		Sep. 30, 2013		Sep. 30, 2014		Sep. 30, 2013		Dec. 31, 2013
Reclassification Out of Accumulated Other Comprehensive Loss [Roll Forward]	'		'		'		'		'
Balance at January 1, 2014	'		'		($202)		'		'
Other comprehensive loss before reclassifications	'		'		-59.7		'		'
Amounts reclassified from accumulated other comprehensive loss	'		'		6		'		'
Balance at September 30, 2014	-255.7		'		-255.7		'		'
Cumulative foreign currency translation adjustments, tax	0		'		0		'		0
Cumulative retirement plans unrealized losses, tax	58.3		'		58.3		'		62
Cumulative unrealized gains on marketable equity securities, tax	1.1		'		1.1		'		1.1
Reclassifications Out of Accumulated Other Comprehensive Loss [Abstract]	'		'		'		'		'
Income tax (benefit) expense	-48.6		31.7		-84.1		96.2		'
Net Income (Loss)	158.6		1.9		297.4		-41.8		'
Cumulative Foreign Currency Translation Adjustments	'		'		'		'		'
Reclassification Out of Accumulated Other Comprehensive Loss [Roll Forward]	'		'		'		'		'
Balance at January 1, 2014	'		'		-98.4	[1]	'		'
Other comprehensive loss before reclassifications	'		'		-57.6	[1]	'		'
Amounts reclassified from accumulated other comprehensive loss	'		'		0	[1]	'		'
Balance at September 30, 2014	-156	[1]	'		-156	[1]	'		'
Cumulative Retirement Plans Unrealized Losses	'		'		'		'		'
Reclassification Out of Accumulated Other Comprehensive Loss [Roll Forward]	'		'		'		'		'
Balance at January 1, 2014	'		'		-103.4	[2]	'		'
Other comprehensive loss before reclassifications	'		'		0	[2]	'		'
Amounts reclassified from accumulated other comprehensive loss	'		'		5.9	[2]	'		'
Balance at September 30, 2014	-97.5	[2]	'		-97.5	[2]	'		'
Cumulative Unrealized Gains on Marketable Equity Securities	'		'		'		'		'
Reclassification Out of Accumulated Other Comprehensive Loss [Roll Forward]	'		'		'		'		'
Balance at January 1, 2014	'		'		1.5	[1]	'		'
Other comprehensive loss before reclassifications	'		'		-2.1	[1]	'		'
Amounts reclassified from accumulated other comprehensive loss	'		'		0	[1]	'		'
Balance at September 30, 2014	-0.6	[1]	'		-0.6	[1]	'		'
Cumulative Gains on Terminated Cash Flow Hedges	'		'		'		'		'
Reclassification Out of Accumulated Other Comprehensive Loss [Roll Forward]	'		'		'		'		'
Balance at January 1, 2014	'		'		-1.7	[3]	'		'
Other comprehensive loss before reclassifications	'		'		0	[3]	'		'
Amounts reclassified from accumulated other comprehensive loss	'		'		0.1	[3]	'		'
Balance at September 30, 2014	-1.6	[3]	'		-1.6	[3]	'		'
Reclassification out of Accumulated Other Comprehensive Income	'		'		'		'		'
Reclassifications Out of Accumulated Other Comprehensive Loss [Abstract]	'		'		'		'		'
Net Income (Loss)	2.1		3.2		6		12.3		'
Reclassification out of Accumulated Other Comprehensive Income | Cumulative Retirement Plans Unrealized Losses	'		'		'		'		'
Reclassifications Out of Accumulated Other Comprehensive Loss [Abstract]	'		'		'		'		'
Income tax (benefit) expense	-1.1		-1.9		-3.7		-5.6		'
Amortization of pension plans actuarial losses	3.1	[4]	4.7	[4]	9.3	[4]	14.3	[4]	'
Amortization of medical and dental plans actuarial losses	0.1	[4]	0.1	[4]	0.3	[4]	0.3	[4]	'
Total amortization before income taxes	3.2		4.8		9.6		14.6		'
Net Income (Loss)	2.1		2.9		5.9		9		'
Reclassification out of Accumulated Other Comprehensive Income | Cumulative Unrealized Gains on Marketable Equity Securities	'		'		'		'		'
Reclassifications Out of Accumulated Other Comprehensive Loss [Abstract]	'		'		'		'		'
Impairment on marketable equity securities	0		0.4		0		3.5		'
Income tax (benefit) expense	0		0		0		0		'
Net Income (Loss)	0		0.4		0		3.5		'
Reclassification out of Accumulated Other Comprehensive Income | Cumulative Gains on Terminated Cash Flow Hedges	'		'		'		'		'
Reclassifications Out of Accumulated Other Comprehensive Loss [Abstract]	'		'		'		'		'
Amortization of loss on terminated cash flow hedges	0		-0.1		0.1		-0.2		'
Income tax (benefit) expense	0		0		0		0		'
Net Income (Loss)	$0		($0.10)		$0.10		($0.20)		'
[1]	Net of taxes of $0.0 million as of SeptemberB 30, 2014 and DecemberB 31, 2013.
[2]	Net of taxes of $58.3 million and $62.0 million as of SeptemberB 30, 2014 and DecemberB 31, 2013, respectively
[3]	Net of taxes of $1.1 million as of SeptemberB 30, 2014 and DecemberB 31, 2013.
[4]	These components are included in the computation of net periodic benefit cost. See Note 17 for additional details.

Earnings_Per_Share_Details

Earnings Per Share (Details)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Weighted average basic common shares outstanding (shares)	168.9	165.7	167.7	165.5
Incremental shares outstanding related to stock-based awards (shares)	2.9	1.3	2.5	0
Weighted average dilutive common shares outstanding (shares)	171.8	167	170.2	165.5
Outstanding Stock Awards	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Outstanding options with exercise price of the options exceeding the average stock price (in shares)	0.3	8.2	3.7	8.5
Incremental common shares related to stock-based awards excluded from computation of earnings per share because of the net loss and the awards related anti-dillutive effect (shares)	'	'	'	1

Incentive_Stock_Program_Detail

Incentive Stock Program (Details) (USD $)	1 Months Ended	3 Months Ended		9 Months Ended
In Millions, except Share data, unless otherwise specified	31-May-14	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award	'	'	'	'	'
Stock-based compensation expense	'	$11.60	$10.40	$40.30	$31.10
Unrecognized compensation costs related to non-vested share-based compensation arrangements	'	87.6	'	87.6	'
Period over which unrecognized compensation cost is expected to be recognized (in years)	'	'2 years 1 month	'	'	'
Stock option award	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award	'	'	'	'	'
Granted (shares)	'	'	'	1,400,000	'
Vesting period, low end of range (in years)	'	'	'	'4 years	'
Term	'	'	'	'7 years	'
2004 Long Term Stock Incentive Plan	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award	'	'	'	'	'
Extended term of the plan	'10 years	'	'	'	'
Increase in number of shares that may be granted	10,000,000	'	'	'	'
Stock-based compensation expense	'	11.6	10.4	40.3	31.1
Income tax benefit recognized	'	$4.20	$3.80	$14.70	$11.40

Incentive_Stock_Program_Detail1

Incentive Stock Program (Details 2) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Stock option award	'	'	'	'
Weighted average fair value and weighted average assumptions	'	'	'	'
Volatility (percent)	27.70%	31.50%	27.70%	30.30%
Expected life (in years)	'4 years 8 months 12 days	'5 years 1 month 6 days	'4 years 8 months 12 days	'5 years 1 month 10 days
Risk-free interest rate (percent)	1.70%	1.30%	1.50%	0.90%
Dividend yield (percent)	0.00%	0.00%	0.00%	0.00%
Fair value per stock option (usd per share)	$13.94	$11.77	$11.37	$8.48
Restricted Stock and Performance Share Awards	'	'	'	'
Vesting period, low end of range (in years)	'	'	'4 years	'
Performance stock awards	'	'	'	'
Weighted average fair value and weighted average assumptions	'	'	'	'
Volatility (percent)	'	'	30.80%	30.80%
Risk-free interest rate (percent)	'	'	0.60%	0.40%
Dividend yield (percent)	'	'	0.00%	0.00%
Fair value per stock option (usd per share)	'	'	$54.14	$29.46
Restricted Stock and Performance Share Awards	'	'	'	'
Granted (in shares)	'	'	100,000	'
Performance cycle (in years)	'	'	'3 years	'
Performance share awards earned, low end of the range (as a percent)	'	'	0.00%	'
Performance share awards earned, high end of the range (as a percent)	'	'	200.00%	'
Restricted stock awards	'	'	'	'
Restricted Stock and Performance Share Awards	'	'	'	'
Granted (in shares)	'	'	900,000	'
Weighted average grant date fair value, at the end of the period (in dollars per share)	$43.65	$29.53	$43.65	$29.53
Minimum | Restricted stock awards	'	'	'	'
Restricted Stock and Performance Share Awards	'	'	'	'
Vesting period, low end of range (in years)	'	'	'1 year	'
Maximum | Restricted stock awards	'	'	'	'
Restricted Stock and Performance Share Awards	'	'	'	'
Vesting period, low end of range (in years)	'	'	'3 years	'

Commitments_and_Contingencies_

Commitments and Contingencies (Details) (Derivative Securities Litigation)	9 Months Ended
	Sep. 30, 2014
	Lawsuit
Derivative Securities Litigation	'
Loss Contingencies	'
Number of lawsuits	2

Segment_Information_Details

Segment Information (Details) (USD $)

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

21 Months Ended

3 Months Ended

9 Months Ended

In Millions, unless otherwise specified

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Segment

Americas

Americas

Americas

Americas

EMEA

EMEA

EMEA

EMEA

APAC

APAC

APAC

APAC

Operating segments

Operating segments

Operating segments

Operating segments

Corporate functions

Corporate functions

Corporate functions

Corporate functions

Device Strategy

Device Strategy

Device Strategy

Device Strategy

Device Strategy

Device Strategy

Device Strategy

Device Strategy

Device Strategy

units

units

units

Americas

Americas

Americas

Americas

Net Sales

Net Sales

Net Sales

Net Sales

Americas

EMEA

APAC

Segment Reporting Information

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reportable segments number

3

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Operating units number

'

'

'

'

'

'

3

'

'

'

1

'

'

'

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net Sales

$1,150.60

$1,008.20

$3,337.20

$2,918.40

$939

$804.20

$2,694

$2,318.90

$135.10

$123.50

$400.50

$369.90

$76.50

$80.50

$242.70

$229.60

$1,150.60

$1,008.20

$3,337.20

$2,918.40

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation

-11.6

-10.4

-40.3

-31.1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Income (Loss) From Operations

227.5

29.8

426.6

-36.6

277.1

75.7

557.7

147.5

-15

-14.5

-40.8

-73.5

2.4

-1.5

15.5

-16.7

264.5

59.7

532.4

57.3

-25.4

-19.5

-65.5

-62.8

'

'

'

'

'

'

'

'

'

Interest expense and Other expense, net

-23.5

-62.3

-60.3

-114.1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Income (Loss) Before Income Taxes

204

-32.5

366.3

-150.7

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Charges incurred

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$243.50

$3.30

$18.90

$16.60

$217.40

$104.30

$88.40

$13.20

$2.70